Programm zur GASL 2016

Transcription

January 22-23, 2016
Düsseldorf
2016
32. Annual Meeting of the German
Association for the Study of the Liver
(GASL) in Düsseldorf
Preliminary Program
Klinik für Gastroenterologie,
Hepatologie und Infektiologie
Leber- Infektionszentrum Düsseldorf
SFB974
Kommunikation und Systemrelevanz
bei Leberschädigung und Regeneration
32nd Annual Meeting of the
German Association for the
Study of the Liver
January 22-23, 2016
Falk Workshop
“Communication and
System Relevance in
Liver Damage
and Regeneration”
January, 21-22, 2016
32. Annual Meeting of the German
Association for the Study of the Liver
(GASL) in Düsseldorf
January 22-23, 2016
President 2015/2016
Prof. Dr. med. Dieter Häussinger
Professor and Chairman
Department of Internal Medicine
Gastroenterology, Hepatology and
Infectious Diseases
Universitätsklinikum Düsseldorf
GASL Secretary
Prof. Dr. med. Verena Keitel
Infectious Diseases
Dear colleagues, dear GASL-members,
I am delighted to welcome you to the 32nd Annual GASL Meeting
at the Heinrich-Heine University and the Universitätsklinikum
Düsseldorf.
The Annual GASL Meeting is held traditionally together with a
GASL workshop entitled “Communication and System Relevance in
Liver Damage and Regeneration”, which is also the title of our
Collaborative Research Center (SFB) 974, which just continued into
the second term. We were able to win internationally renowned
experts in the field of hepatology to provide insights into signals
that regulate the switch between liver regeneration and liver
damage and fibrosis development as well as on the system relevance of these processes. I
would like to thank Ursula Falk and the Falk Foundation for sponsoring this workshop.
The GASL Annual Meeting will focus on 5 topics: 1. Fibrogenesis and nonparenchymal cells,
2. Clinical hepatology, 3. Metabolism and Transport, 4. Tumors, liver surgery and liver
transplantation, 5. Viral hepatitis and immunology. Out of the 196 submitted abstracts the
GASL program committee has selected 3 contributions per topic for short talks. The authors
of posters will have time to present their work during the official poster viewing times both
to the GASL participants as well as to the members of the poster committee.
I would also like to welcome our keynote speaker, Professor Dr. Helen Hobbs from UT
Southwestern, who is an expert in the field of genetic liver disease, with an emphasis on lipid
metabolism. She will give a keynote lecture entitled “Fatty Liver Disease: Ancient mutations
for a common disease”. Her laboratory recently not only identified polymorphism in the
PNPLA3 and TM6SF2 gene as genetic determinants for NAFLD, but also provided exciting
new insights into the pathomechanisms linking these genetic variants to lipid accumulation
in the liver using animal studies.
My special thanks go to all sponsors of GASL 2016 for their generous support. I would also
like to thank all participants for your contribution to this meeting. Furthermore, my
gratitude goes to the GASL program committee as well as my local organizing team, who all
made this meeting possible.
I look forward to a stimulating meeting and exchange of novel ideas and data. This should
extend beyond the scientific sessions and continue into our scientific and social dinner event
at the Rheinterrassen Düsseldorf.
Sincerely,
Venue
Heinrich-Heine University, Building 23.01, Lecture Hall 3D and foyer
Universitätsstraße 1
40225 Düsseldorf
Prof. Dr. Dieter Häussinger
GASL President 2015/2016
Direktor der Klinik für Gastroenterologie,
Hepatologie und Infektiologie
Sprecher des Sonderforschungsbereichs (SFB) 974 und der
Klinischen Forschergruppe (KFO) 217
General Information
GASL 2016
Table of Contents
Welcome............................................................................................................ 5
General Information .......................................................................................... 7
Program Overview........................................................................................... 10
Program .......................................................................................................... 13
GASL 2016 President
Infectious Diseases
Moorenstr.5, 40225 Düsseldorf
Venue
Heinrich-Heine University
Building 23.01
Lecture Hall 3D and foyer
40225 Düsseldorf
Start of Meeting
Friday, January 22, 2016
12:30
Registration opens after 11:00
End of Meeting
Saturday, January 23, 2016
14:30
Session 1: Fibrogenesis and Nonparenchymal Cells ...................................... 13
Session 2: Clinical Hepatology ...................................................................... 24
Session 3: Metabolism and Transport .......................................................... 38
Session 4: Tumors, Liver Surgery and Transplantation ................................. 47
Session 5: Viral Hepatology and Immunology ............................................... 57
GASL Secretary
Infectious Diseases
Moorenstr. 5, 40225 Düsseldorf
GASL Presidents and Secretaries .................................................................... 64
Campus and Maps .......................................................................................... 65
Sponsors of GASL 2016 .................................................................................... 67
Impressum ....................................................................................................... 68
Index ................................................................................................................ 70
nd
32 Annual Meeting of the German Association for the Study of the Liver
-6-
GASL Program Committee
PD Dr. med. Ana Paula Barreiros Clara, Regensburg
Prof. Dr. rer. nat. Mathias Heikenwälder, München
Prof. Dr. med. Thomas Longerich, Aachen
PD Dr. med. Andreas Schnitzbauer, Frankfurt
PD Dr. med. Thomas von Hahn, Hannover
Dr. med. Marcin Krawczyk, Homburg
nd
Online Registration
Online registration via
Conventus until December
31, 2015
at www.gasl.de
Fee: 65 €
Students: free
On Site Registration
Fee: 80 €
Students: free
-7-
Die HCV-Therapie von AbbVie
Denn jeder Patient zählt!
Overview of the Scientific Program
Dinner Event
Session 1: Fibrogenesis and Nonparenchymal Cells
Session 2: Clinical Hepatology
Session 3: Metabolism and Transport
Session 4: Tumors, Liver Surgery and
Transplantation
Session 5: Viral Hepatitis and Immunology
Each session includes poster visits, lectures and a
poster discussion.
We look forward to a relaxing
evening at the Rheinterrassen
located directly at the riverside of
the Rhine. Please join us for a
scientific dinner event following the
plenary session at 19:30. Bus
transfer is available. Registration is
required. A registration fee of 50 €
will cover dinner buffet, drinks and
music.
Keynote Speaker
Saturday, Jan. 23, 2016, 10:45-11:30.
Prof. Helen Hobbs, Ph.D., UT Southwestern Medical
Center, Dallas
State-of-the-Art lecture on “Fatty Liver Disease:
Ancient mutations for a common disease”
Bis zu
SVR
im großen und robusten Studienprogramm *1,2
Local Organizers
Prof. Dr. med. Johannes Bode
Prof. Dr. rer. nat. Holger Gohlke
Prof. Dr. med. Philipp Lang
Dr. rer. nat. Radmila Feldmann
Congress Organisation
Conventus Congressmanagement & Marketing
GmbH
Media Information
* 95-100 % SVR für GT1-Patienten und 100 % SVR für GT4-Patienten ohne Zirrhose 1. Fachinformation viekirax, Stand Juli 2015 2. Fachinformation exviera, Stand Juli 2015
Presentations: Please visit the media table in front
of lecture hall 3D in order to transfer your
presentation file.
Posters: Posters are displayed in the foyer of the
building 23.01 at the upper and lower levels. Please
visit the media table for assistance.
WiFi Internet
Data for login will be provided at the registration
table.
CME Credits Application for CME credits submitted.
nd
-8-
Viekirax® 12,5 mg/75 mg/50 mg Filmtabletten. Bezeichnung des Arzneimittels: Viekirax 12,5 mg/75 mg/50 mg Filmtabletten. Wirkstoffe: Ombitasvir, Paritaprevir, Ritonavir.
Zusammensetzung: Jede Filmtablette enthält 12,5 mg Ombitasvir, 75 mg Paritaprevir und 50 mg Ritonavir. Sonstige Bestandteile: Tablettenkern: Copovidon, Tocofersolan, Propylenglykolmonolaurat, Sorbitanlaurat, hochdisperses Siliciumdioxid, Natriumstearylfumarat; Überzug: Poly(vinylalkohol), Polyethylenglykol 3350, Talkum, Titandioxid, Eisen(III)-oxid. Anwendungsgebiete:
Viekirax wird in Kombination mit anderen Arzneimitteln zur Behandlung der chronischen Hepatitis C (CHC) bei Erwachsenen angewendet. Zur spezifischen Aktivität gegen die verschiedenen
Genotypen des Hepatitis-C-Virus (HCV) siehe Fachinformation. Gegenanzeigen: Überempfindlichkeit gegen einen der Wirkstoffe oder sonstigen Bestandteile. Schwere Leberfunktionsstörung
(Child-Pugh C). Ethinylestradiol. Sensitive CYP3A-Substrate wie Alfuzosinhydrochlorid, Amiodaron, Astemizol, Atorvastatin, Chinidin, Cisaprid, Colchicin (bei Patienten mit Nieren- oder Leberfunktionsstörung), Dihydroergotamin, Ergometrin, Ergotamin, Fusidinsäure, Lovastatin, Methylergometrin, oral angewendetes Midazolam, Pimozid, Quetiapin, Salmeterol, Sildenafil (bei Behandlung
einer pulmonalen arteriellen Hypertonie), Simvastatin, Terfenadin, Ticagrelor, Triazolam. Starke oder moderate CYP3A4-Induktoren wie Carbamazepin, Efavirenz, Enzalutamid, Etravirin, Johanniskraut, Mitotan, Nevirapin, Phenobarbital, Phenytoin, Rifampicin. Starke CYP3A4-Inhibitoren wie Clarithromycin, Cobicistat, Conivaptan, Indinavir, Itraconazol, Ketoconazol, Lopinavir/Ritonavir,
Posaconazol, Saquinavir, Telithromycin, Tipranavir, Voriconazol. Nebenwirkungen: In Kombination mit Dasabuvir: häufig: Pruritus. In Kombination mit Dasabuvir und Ribavirin: sehr häufig:
Asthenie, Erschöpfung, Pruritus, Schlaflosigkeit, Übelkeit; häufig: Anämie. ALT erhöht. Hämoglobin erniedrigt. Bilirubin erhöht. Verschreibungspflichtig. Stand Juli 2015. Pharmazeutischer
Unternehmer: AbbVie Ltd, Maidenhead, SL6 4UB, Vereinigtes Königreich.
Exviera® 250 mg Filmtabletten. Bezeichnung des Arzneimittels: Exviera 250 mg Filmtabletten. Wirkstoff: Dasabuvir. Zusammensetzung: Jede Filmtablette enthält 250 mg Dasabuvir.
Sonstige Bestandteile: Tablettenkern: Mikrokristalline Cellulose, Lactose-Monohydrat, Copovidon, Croscarmellose-Natrium, hochdisperses Siliciumdioxid, Magnesiumstearat; Überzug: Poly(vinylalkohol), Titandioxid, Polyethylenglycol 3350, Talkum, Eisen(III)-hydroxid-oxid x H2O, Eisen(III)-oxid, Eisen(II,III)-oxid. Anwendungsgebiete: Exviera wird in Kombination mit anderen Arzneimitteln
zur Behandlung der chronischen Hepatitis C (CHC) bei Erwachsenen angewendet. Zur spezifischen Aktivität gegen die verschiedenen Genotypen des Hepatitis-C-Virus (HCV) siehe Fachinformation.
Gegenanzeigen: Überempfindlichkeit gegen einen der Wirkstoffe oder sonstigen Bestandteile. Ethinylestradiol. Starke oder moderate Enzyminduktoren wie Carbamazepin, Efavirenz, Enzalutamid,
Etravirin, Johanniskraut, Mitotan, Nevirapin, Phenobarbital, Phenytoin, Rifampicin. Starke CYP2C8-Inhibitoren wie Gemfibrozil. Nebenwirkungen: In Kombination mit Ombitasvir/Paritaprevir/
Ritonavir: häufig: Pruritus. In Kombination mit Ombitasvir/Paritaprevir/Ritonavir und Ribavirin: sehr häufig: Asthenie, Erschöpfung, Pruritus, Schlaflosigkeit, Übelkeit; häufig: Anämie. ALT erhöht.
Hämoglobin erniedrigt. Bilirubin erhöht. Warnhinweis: Enthält Lactose. Verschreibungspflichtig. Stand Juli 2015.
Pharmazeutischer Unternehmer: AbbVie Ltd, Maidenhead, SL6 4UB, Vereinigtes Königreich.
AbbVie Deutschland GmbH & Co. KG · Mainzer Straße 81 I 65189 Wiesbaden
Tel: +49 (0)611 / 1720 – 0 · Fax: +49 (0)611 / 1720 – 1244 I E-Mail: [email protected]
14:3515:20
15:2016:05
Clinical Hepatology
14:1014:35
16:0516:30
16:3017:15
17:1518:00
18:0018:25
18:2518:35
18:3518:45
18:4519:30
19:30
GASL 2016 President
Dieter Häussinger, Düsseldorf
Chair: Fabian Geisler, Munich
A. Ghallab, Dortmund
W. Reul, Bonn
J.-M. Bangen, Aachen
Lectures
Poster Discussion
Moderator: Monika Rau, Würzburg
Poster Visit Session II
and Coffee Break
A. Barreiros Clara, Program Committee
T. von Hahn, Program Commitee
T. Bruns, Jena
F. Grünhage, Homburg
J. Bode, Düsseldorf
Lectures
Chair: Frank Grünhage, Homburg
J. Hartl, Hamburg
B. Frieg, Düsseldorf
V. Sauer, Münster
Poster Discussion
Moderator: Tony Bruns, Jena
08:3009:15
09:1510:00
10:0010:25
11:4012:25
M. Heikenwälder, Program Committee
Poster Visit Session III A. Kremer, Erlangen
A. Pathil-Warth, Heidelberg
and Coffee Break
J. Marquardt, Mainz
Lectures
Chair: Moritz Schmelzle, Berlin
C. Koppe, Aachen
M. Tautenhahn, Leipzig
S. Brunner, Regensburg
Poster Discussion
Moderator: Falk Rauchfuß, Jena
Keynote Lecture:
“ Fatty Liver Disease: Ancient
10:2510:55
10:5511:40
Poster Visit Session IV and
Coffee Break
A. Schnitzbauer, Program
Committee
T. Longerich, Program Committee
M. Schmelzle, Berlin
F. Rauchfuß, Jena
mutations for a common
disease ”
12:2512:50
Helen Hobbs, UT Southwestern
Medical Center, Dallas
Poster Visit Session V and
Brunch
T. von Hahn, Program Committee
S. Ciesek, Hannover
J. Nattermann, Bonn
C. Lange, Frankfurt
C. Neumann-Haefelin, Freiburg
Lectures
Chair: Sandra Ciesek, Hannover
J. Kah, Hamburg
F. Rinker, Hannover
D. Kaczmarek, Bonn
Poster Discussion
Moderator: Christian Lange,
Frankfurt
D. Nierhoff, Cologne
Chair: Anita Pathil-Warth, Heidelberg
S. Weber, Homburg
H. Hermanns, Würzburg
J. Henkel, Potsdam
Lectures
Poster Discussion
Moderator: Andreas Kremer, Erlangen
Prize Ceremony
12:5014:30
Invitation to GASL 2017
GASL President’s closing words
GASL Prize (YAEL Foundation) Ceremony
Lucie-Bolte Prize Ceremony
GASL Plenary Meeting
Scientific Dinner, Rheinterrassen
nd
- 10 -
nd
- 11 -
Program Overview
Opening
Saturday, January 23, 2016
Tumors, Liver Surgery and
Transplanatation
13:2514:10
Poster Visit Session I
and Lunch Break
M. Krawczyk, Program Committee
V. Keitel, Program Committee
M. Rau, Würzburg
F. Geisler, Munich
F. Tacke, Aachen
Viral Hepatitis and
Immunology
13:1513:25
Fibrogenesis and
Nonparenchymal Cells
12:3013:15
Metabolism and Transport
Program Overview
Friday, January 22, 2016
Presentations
1.1
Intravital real time imaging of liver damage and regeneration by functional twophoton microscopy
Ghallab A.1, Reif R.1, Hassan R.1, Seddek A.2, Hengstler J. G.1
1
Leibniz Research Centre for Working Environment and Human Factors (IFADo),
Systems toxicology, Dortmud, Germany
2
South Valley University, Faculty of Veterinary Medicine, Department of Forensic
Medicine and Toxicology, Qena, Egypt
CHEN
O
W
2
1
T3
1.2
GRHOSE
FOHÜNR
E ZIRINFREI
Neprilysin controls the switch between hepatic vasoconstriction and fibrogenesis
Klein S.1, Reul W. Heinrich1, Schierwagen R.1, Uschner F. Erhard1, Strassburg C.
Peter1, Walther T.3, Trebicka J.1
1
V IR
RIBA
1
University Hospital of Bonn, Internal medicine I, Bonn, Germany
University of Leipzig, Department of Obstetrics, Centre for Perinatal Medicine,
Division of Women and Child Health, Leipzig, Germany
3
University College Cork, Department of Pharmacology and Therapeutics, Cork,
Ireland
IHR ERFOLG MIT DAKLINZA
2
®
BEI CHRONISCHER HEPATITIS C
Heilung* für fast alle Ihre Patienten mit hohem therapeutischen Bedarf 1,2 –
insbesondere
• Patienten mit Genotyp 3
• Patienten mit fortgeschrittener Lebererkrankung
1.3
Der hochwirksame NS5A-Inhibitor DAKLINZA®
in Kombination mit Sofosbuvir:1,2
Posters
Bangen J. M., Hammerich L., Tacke F., Trautwein C., Liedtke C.
RWTH Aachen University, Department of Internal Medicine III, Aachen, Germany
1.4
Stark wirksam auch
ohne Ribavirin**,1,2
Sehr gute
Verträglichkeit 1,2
A computational multi-scale model for the integration of paracrine stimuli
activating NF-kB signalling in hepatocytes after lipopolysaccharide (LPS) treatment
Beuke K.1, Schildberg F.2, Pinna F.3, Albrecht U.4, Liebe R.5, Bissinger M.3,
Schirmacher P.3, Dooley S.5, Bode J.4, Knolle P.2, Kummer U.1, Sahle S.1, Breuhahn K.3
Einfache
Anwendung 1
1
University of Heidelberg, Department of Modelling of Biological Processes, COS
Heidelberg, Heidelberg, Germany
2
Technische Universität München, Institute of Molecular Immunology &
Experimental Oncology, München, Germany
3
University Hospital of Heidelberg, Institute of Pathology, Heidelberg, Germany
4
University Hospital of Düsseldorf, Department of Gastroenterology, Hepatology
and Infectious Disease, Düsseldorf, Germany
5
Medical Faculty Mannheim, Department of Medicine II, Section Molecular
Hepatology, Mannheim, Germany
www.bms-virologie.de
* Langzeit-Follow-up-Studien haben gezeigt, dass eine SVR12 in über 99 % der Fälle einer endgültigen Ausheilung der HCV-Infektion entspricht.3,4
** GT3 ohne Zirrhose: 12 Wochen in Kombination mit Sofosbuvir; GT3 mit Zirrhose: 24 Wochen in Kombination mit Sofosbuvir. Zugabe von Ribavirin individuell möglich.
1392DE15PR09601
Referenzen:
1. Daklinza® Fachinformation. Stand September 2015. 2. Nelson DR et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology 2015;61(4):1127–1135.
3. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63(1):199–236. 4. Swain MG et al. A sustained virologic response is durable in patients with chronic hepatitis C
treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139(5):1593–1601.
Daklinza 30 mg Filmtabletten. Daklinza 60 mg Filmtabletten. Wirkstoff: Daclatasvir. Zusammensetzung: Wirkstoff: 30 mg bzw. 60 mg Daclatasvir. Sonst. Bestandteile: Lactose, Mikrokristalline Cellulose, Croscarmellose-Natrium,
Siliciumdioxid (E551), Magnesiumstearat, Hypromellose, Titandioxid (E171), Macrogol 400, Indigocarmin Aluminiumsalz (E132), Gelbes Eisenoxid (E172). Anwendungsgebiete: In Kombination mit anderen Arzneimitteln zur Behandlung der
chronischen Infektion mit dem Hepatitis-C-Virus (HCV) bei Erwachsenen. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff od. einen d. sonst. Bestandteile; Koadministration mit Arzneimitteln, die starke Induktoren für CYP3A4 und P-gp sind,
da dies zu einer geringeren Exposition und Wirksamkeitsverlust führen kann (z.B. Phenytoin, Carbamazepin, Oxcarbazepin, Phenobarbital, Rifampicin, Rifabutin, Rifapentin, systemisch angewendetes Dexamethason, Johanniskraut). Nebenwirkungen:
Daklinza + Sofosbuvir – sehr häufig: Kopfschmerz; Ermüdung; häufig: Schlaflosigkeit; Schwindelgefühl, Migräne; Übelkeit, Diarrhoe, Bauchschmerzen, Arthralgie, Myalgie. Daklinza + Sofosbuvir + Ribavirin – sehr häufig: Anämie; Kopfschmerz;
Husten; Übelkeit; Pruritus; Ermüdung; häufig: verminderter Appetit; Schlaflosigkeit, Reizbarkeit; Schwindelgefühl, Migräne; Hitzewallung; Dyspnoe, Belastungsdyspnoe, nasale Kongestion; Diarrhoe, Erbrechen, Bauchschmerzen, gastroösophageale
Refluxerkrankung, Obstipation, trockener Mund, Flatulenz; Ausschlag, Alopezie, trockene Haut; Arthralgie, Myalgie. Daklinza + Peginterferon alfa + Ribavirin: Ermüdung, Kopfschmerz, Pruritus, Anämie, grippeähnliche Erkrankung, Übelkeit,
Schlaflosigkeit, Neutropenie, Asthenie, Ausschlag, verminderter Appetit, trockene Haut, Alopezie, Pyrexie, Myalgie, Reizbarkeit, Husten, Diarrhoe, Dyspnoe, Arthralgie, Lymphopenie, Thrombozytopenie. Weitere Hinweise: siehe Fachinformation.
Verschreibungspflichtig. Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung über das nationale Meldesystem anzuzeigen. Pharmazeutischer
Unternehmer: Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH Vereinigtes Königreich. Stand: Q3/2015
Targeting liver fibrosis by siRNA-mediated inhibition of Cyclin E1 in mice
nd
- 13 -
Fibrogenesis and Nonparenchymal Cells
DAKLINZA® (Daclatasvir):
Ihr starker Partner für eine effektive Therapie1,2
A disintegrin and metalloprotease 10 (ADAM10) is a central regulator of liver
tissue homeostasis
1.8
Kordes C., Sawitza I., Götze S., Häussinger D.
Müller M.1, Wetzel S.1, Köhn-Gaone J.2, Chalupsky K.3, Lüllmann-Rauch R.4, Barikbin
R.5, Wöhner B.1, Tiegs G.5, Rose-John S.1, Sedlacek R.3, Tirnitz-Parker J. E.6, Saftig P.1,
Schmidt-Arras D.1
1
Christian-Albrechts-University, Institute of Biochemistry, Kiel, Germany
Curtin University, School of Biomedical Sciences, Curtin Health Innovation Research
Institute, Faculty of Health Sciences, Bentley, Australia
3
Institute of Molecular Genetics of the ASCR, Laboratory of Transgenic Models of
Disease, Prague, Czech Republic
4
Christian-Albrechts-University, Institute of Anatomy, Kiel, Germany
5
University Medical Center Hamburg-Eppendorf, Institute of Experimental
Immunology and Hepatology, Hamburg, Germany
6
University of Western Australia, School of Biomedicine, Freemantle, Australia
Heinrich Heine University, Clinic of Gastroenterology, Hepatology and Infectious
Diseases, Duesseldorf, Germany
1.9
2
1.6
A human hepatic in vitro co-culture system for the analysis of DILI related
signaling
1
University of Cologne, Germany, Department of Gastroenterology and Hepatolog,
Cologne, Germany
2
Medical University of Graz, Austria, Research Unit for Experimental and Molecular
Hepatology, Division of Gastroenterology and Hepatology, Graz, Austria
3
Medical University of Graz, Institute of Pathology, Graz, Austria
1.10
German Federal Institute for Risk Assessment (BfR), Department of Chemical and
Product Safety, Berlin, Germany
2
UFZ, Helmholtz-Centre for Environmental Research, Department of Proteomics,
Leipzig, Germany
3
UFZ, Helmholtz-Centre for Environmental Research, Department of Metabolomics,
Leipzig, Germany
4
Aalborg University, Department of Chemistry and Bioscience, Aalborg, Denmark
1
Heinrich-Heine-University of Düsseldorf, Clinic for Gastroenterology, Hepatology
and Infectiology, Düsseldorf, Germany
2
University of Stuttgart, Institute for System Dynamics, Stuttgart, Germany
3
Heinrich-Heine-University of Düsseldorf, Biological and Medical Research Center,
Düsseldorf, Germany
4
Hannover Medical School, Institute of Physiological Chemistry, Hannover, Germany
1.11
Das synthetische Chaperon 4-PBA induziert eine Akut-Phase-Reaktion im MausModell für Protein-Speicherkrankheiten
Schneider F., Churin Y., Köppel A., Baier K. Maria, Tschuschner A., Roderfeld M.,
Roeb E.
Glaser F.1, Engel B.1, John C.2, Krech T.3, Carambia A.1, Herkel J.1, Lohse A. W.1,
Heeren J.2, Schramm C.1, Schwinge D.1
Justus-Liebig-Universität, Molekulare Gastroenterologie, Gießen, Deutschland
1
University Medical Center Hamburg-Eppendorf, I. Department of Internal
Medicine, Hamburg, Germany
2
University Medical Center Hamburg-Eppendorf, Department of Biochemistry and
Molecular Cell Biology, Hamburg, Germany
3
University Medical Center Hamburg-Eppendorf, Department of Pathology,
Hamburg, Germany
Crucial role of the interplay of the MAPKAP kinases 2 and 3 for LPS-induced
inflammation and their relevance for liver pathogenesis
Ehlting C.1, Sanwald J.2, Albrecht U.1, Deenen R.3, Köhrer K.3, Gaestel M.4, Feuer R.2,
Sawodny O.2, Häussinger D.1, Bode J. G.1
1
A new mouse model of sclerosing cholangitis combining toxic and immune
mediated bile duct injury
Cholestasis induces expression of the oncofetal marker Nope in adult murine liver
independent of Fxr
Bowe A.1, Hoffmann V.1, Curth H. Morten1, Fickert P.2,3, Nierhoff D.1
Wewering F.1, Jouy F.2, Wissenbach D. K. W. K.3, Gebauer S.3, von Bergen M.2, Luch
A.1, Kalkhof S.2, Zellmer S.1
1.7
Beyond fibrosis: stellate cells as liver stem cells
1.12
Deletion of WISP1 leads to higher sensitivity to carbon tetrachloride-induced liver
damage
Pütter L.1, Campos G.1, Rochlitz K.1, Dahmen U.2, Hengstler J. G.1, Godoy P.1
1
Leibniz Research Centre for Working Environment and Human Factors (IfADo),
Technical University Dortmund, Systems Toxicology, Dortmund, Germany
2
University Hospital of Jena, Experimental Graft Surgery, Jena, Germany
nd
- 14 -
nd
- 15 -
1.5
Delta like ligand4 modulates chemokine ligand 2 through impacting the NFkB
pathway
1.17
Dewidar B.1, Shen Z.3, Li Y.3, Dooley S.1, Weng H.-L.1
Benz F.1, Roderburg C.1, Roy S.1, Tacke F.1, Neumann U. Peter2, Trautwein C.1,
Luedde T.1
1
Heidelberg University, Department of Medicine II, Section Molecular Hepatology,
Medical Faculty Mannheim, Mannheim, Germany
2
Tanta University, Department of Pharmacology and Toxicology, Faculty of
Pharmacy, Tanta, Egypt
3
Zhejiang University School of Medicine, Department of Gastroenterology, The First
Affiliated Hospital, Hangzhou, China
1.14
Die Hemmung der Glyoxalase-I durch Ethylpyruvat vermindert den LPSinduzierten Anstieg des portalen Drucks
1
Universitätsklinikum RWTH Aachen, Klinik für Gastroenterologie,
Stoffwechselerkrankungen und Internistische Intensivmedizin – Medizinische Klinik
III, Aachen, Germany
2
Universitätsklinikum RWTH Aachen, Klinik für Allgemein-, Viszeral- und
Transplantationschirurgie, Aachen, Germany
1.18
Heinrich-Heine University, Clinic of Gastroenterology, Hepatology and Infectious
Martin-Luther Universität Halle-Wittenberg, Klinik für Innere Medizin I
Gastroenterologie und Hepatologie, Halle (Saale), Deutschland
Die Repression von miR-192 schützt vor hepatischer
Ischämie/Reperfusionsschädigung
Epigenetic changes contribute to hepatic stellate cell activation
Schumacher E. C, Götze S., Kordes C., Häussinger D.
Hollenbach M., Thonig A., Pohl S., Ripoll C., Greinert R., Michl P., Zipprich A.
1.15
Ein zellspezifisches Netzwerk TGF-beta abhängiger micro-RNAs reguliert
organübergreifende Prozesse in der Fibrogenese
1.19
Erhöhte Mortalität durch leberspezifische Koexpression der profibrogenetischen
Faktoren PDGF-B und TGF-b
Maass T.1, Itzel T.1, Kanzler S.2, Teufel A.1
Roderburg C.1, Roy S.1, Benz F.1, Tacke F.1, Neumann U. Peter2, Trautwein C.1,
Luedde T.1
1
2
1
Universitätsklinikum RWTH Aachen, 1 Klinik für Gastroenterologie,
Stoffwechselerkrankungen und Internistische Intensivmedizin – Medizinische Klinik
III, Aachen, Germany
2
Universitätsklinikum RWTH Aachen, 2 Klinik für Allgemein-, Viszeral- und
Transplantationschirurgie, Aachen, Germany
1.16
1.20
1
Heinrich-Heine University, Institute of Biochemistry and Molecular Biology II,
Düsseldorf, Deutschland
2
Heinrich-Heine University, Clinic of Gastroenterology, Hepatology and Infectious
Diseases, Düsseldorf, Deutschland
Görtzen J.1, Bierwolf J.2, Klein S.1, Schierwagen R.1, Strassburg C. P1, Laleman W.3,
Pollok J. M2, Wells R. G.4, Trebicka J.1
1
University of Bonn, Department of Internal Medicine I, Bonn, Germany
University of Bonn, Department of General, Visceral, Thoracic, and Vascular
Surgery, Bonn, Germany
3
University Hospital Gasthuisberg, Department of Internal Medicine, Leuven,
Belgium
4
Perelman School of Medicine, University of Pennsylvania, Department of Medicine,
Philadelphia, United States of America
nd
- 16 -
Expression, epigenetical regulation and signaling network of embryonic stem cellexpressed RAS in hepatic stellate cells
Nakhaei-Rad S.1, Nakhaeizadeh H.1, Götze S.2, Kordes C.2, Häussinger D.2, Ahmadian
M. R.1
Differential activation of RhoA and c-SRC in experimental and human fibrosis
2
Universität Regensburg, Klinik für Innere Medizin I, Regensburg, Germany
Leopoldina Krankenhaus, Medizinische Klinik 2, Schweinfurt, Germany
1.21
FPR1 might play a relevant role in prevention of liver fibrosis
Giebeler A.1, Brandenburg L.-O.2, Wang J.-M.3, Neumann U.1
1
RWTH Aachen University Hospital, Department of Surgery, Aachen, Germany
RWTH Aachen University Hospital, Department of Anatomy and Cell Anatomy,
Aachen, Germany
3
Center for Cancer Research, National Cancer Institute, National Institute of Health,
Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program,
Fredericks, United States of America
2
nd
- 17 -
1.13
Hepatic Proteome and Lipid Profiling of Wild Type and Lipocalin-2-Deficient Mice
in Experimental Steatosis
1.26
Asimakopoulou A.1, Fülöp A.2, Borkham-Kamphorst E.1, Gassler N.3, Berger T.4, Mak
T. W.5, Hopf C.2, Henkel C.6, Weiskirchen R.1
Freese K.1, Dorn C.1, Thasler W. E2, Müller M.1, Hellerbrand C.1
1
University Hospital Regensburg, Department of Internal Medicine I, Regensburg,
Germany
2
Hospital of the University of Munich, Department of General, Visceral,
Transplantation, Vascular and Thoracic Surgery, Munich, Germany
1
RWTH University Hospital Aachen, Institute of Molecular Pathobiochemistry,
Experimental Gene Therapy and Clinical Chemistry, Aachen, Germany
2
Mannheim University of Applied Sciences, Applied Research Center in Biomedical
Mass Spectrometry (ABIMAS), Instrumental Analysis and Bioanalysis, Mannheim,
Germany
3
Klinikum Braunschweig, Institute of Pathology, Braunschweig, Germany
4
University Health Network, The Campbell Family Institute for Breast Cancer
Research, Toronto, Canada
5
Ontario Cancer Institute, Ontario Cancer Institute, Toronto, Canada
6
ISAS – e.V., Leibniz-Institut für Analytische Wissenschaften, Dortmund, Germany
1.23
Hepatocyte dependent induction of regulatory T-cell subsets
1.27
1.28
RWTH University Hosptial Aachen, Institute of Molecular Pathobiochemistry,
1.29
1
Martin-Luther-University Halle-Wittenberg, First Department of Internal Medicine
I, Halle, Germany
2
Martin-Luther-University Halle-Wittenberg, Julius Bernstein Institute of Physiology,
Halle, Germany
Identification of transcriptional regulatory networks in acute liver damage and
regeneration
LPS and bone morphogenetic protein (BMP)-9 regulate the hepatocytes acute
phase response by affecting hepatic stellate cells
Liebe R.1, Meyer C.1, Chen S.1, Wan F.1, Abramovic K.1, Müller A.1, Gaitantzi H.1,
König C.2, Augustin H.2, Ebert M.1, Dooley S.1, Breitkopf-Heinlein K.1
Wolf A.1, Schreier B.2, Hammer S.1, Pohl S.1, Gekle M.2, Zipprich A.1
1.25
Lipocalin 2 und Perilipin 5 in der Pathogenese der durch Fruktose ausgelösten
NAFLD
Lambertz J., Boaru S. G., Borkham-Kamphorst E., Weiskirchen R.
University Medical Center Hamburg-Eppendorf, Hamburg, Institute of Experimental
Immunology & Hepatology, Hamburg, Germany
Hypoxia and inflammation reduce the expression of the mineralocorticoid
receptor (MR) in the hepatocytes - a mechanism that explains the lower
expression of MR in cirrhosis
Influence of the microbiome in regulating ConA-induced-liver injury
Schiller B., Wegscheid C., Horst A. K., Tiegs G.
Pfaff M., Neumann K., Karimi K., Tiegs G.
1.24
Increased expression of histone deacetylase 7 during hepatic stellate cell
activation promotes pro-fibrogenic gene expression
1
Medical Faculty Mannheim, Heidelberg University, II. Medical Clinic, Mannheim
German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Division of
Vascular Oncology and Metastasis, Heidelberg, Germany
2
1.30
Mast cells inhibit activation and profibrogenic activities of hepatic stellate cells
Meurer S. K, Neß M., Weiskirchen R.
Campos G.1, Schmidt-Heck W.1, Widera A.1, Rochlitz K.1, Leserer S.1, Pütter L.1,
Ghallab A.1, Hengstler J.1, Godoy P.1
1
IfADo-Leibniz Research Centre for Working Environment and Human Factors,
Toxicology, Dortmund, Germany
2
Leibniz Institute for Natural Product Research and Infection Biology - Hans-KnöllInstitute, Systems Biology and Bioinformatics, Jena, Germany
nd
- 18 -
nd
- 19 -
1.22
Regulation and profibrogenic effects of TGF-ɴ1 signaling in mast cells, a cell type
contributing to the outcome of hepatic injury
1.36
Neß M.1, Bangen J. Martin3, Huber M.2, Liedtke C.3, Weiskirchen R.1, Meurer S.
Klaus1
Huynh K. C.1, 2, 3, 4, Nguyen H.1, 2, 3, Stoldt V.1, 2, 3, Scharf R. E.1, 2, 3
1
University of Düsseldorf, Department of Hemostasis, Hemotherapy, and
Transfusion Medicine, Düsseldorf, Germany
2
University of Düsseldorf, NRW research school Biostruct, Düsseldorf, Germany
3
University of Düsseldorf, Biological Medical Research Center, Düsseldorf, Germany
4
International University, Vietnam National Universities - Ho Chi Minh City,
Department of Biomedical Engineering, Ho Chi Minh, Vietnam
1
Experimental Gene Therapy and Clinical Chenistry, Aachen, Germany
2
RWTH University Hospital Aachen, Institute of Biochemistry and Molecular
Immunology, Aachen, Germany
3
RWTH University Hospital Aachen, Department of Internal Medicine III, Aachen,
Germany
1.37
1.32
Overwhelming high quantities of the matricellular protein CCN1/CYR61 induce ER
stress-related cellular apoptosis in hepatic stellate cells
1.33
Heinrich Heine University Düsseldorf Medical Center & Biological Medical Research
Center, Dept. of Experimental and Clinical Hemostasis, Hemotherapy, and
Transfusion Medicine, Düsseldorf, Germany
Platelet integrin-dependent fibrillogenesis of fibronectin: Impact of shear stress
The bile acid-phospholipid conjugate Ursodeoxycholyl
Lysophosphatidylethanolamide (UDCA-LPE) disturbs pro-fibrogenic Integrin and
TGFɴ signaling
Nguyen H. T. T. 1, Huynh K. C.4, Stoldt V. R.1, Scharf R. E.1
Su J., Gan-Schreier H., Chamulitrat W., Stremmel W., Pathil A.
1
University Heidelberg, Department of Internal Medicine IV, Heidelberg, Germany
Heinrich Heine University Medical Center, Dept. of Experimental and Clinical
Hemostasis, Hemotherapy, and Transfusion Medicine, Düsseldorf, Germany
2
Heinrich Heine University, Biological Medical Research Center, Düsseldorf,
Germany
3
Heinrich Heine University, NRW Research School Biostruct, Düsseldorf, Germany
4
International University - Vietnam National University, Department of Biomedical
Engineering, Ho Chi Minh City, Vietnam
1.34
Shear-related fibrillogenesis of fibronectin
Stoldt V. R., Nguyen H.T.T., Scharf R. E.
Borkham-Kamphorst E., Steffen B. T., Van de Leur E., Haas U., Tihaa L., Weiskirchen
R.
Experimental Gene Therapy, and Clinical Chemistry, Aachen, Germany
Shear-induced fibrillar-like supramolecule of plasma fibronectin: A new form of
fibronectin with enhanced activity in platelet adhesion and aggregation
1.38
1.39
The TGR5 protein amount is reduced in patients with primary sclerosing
cholangitis (PSC)
Spomer L.1, Höhne J.1, Hov J.2, Karlsen T.2, Nierhoff D.3, Häussinger D.1, Keitel V.1
1
Heinrich-Heine-University, Clinic for Gastroenterology, Hepatology and Infectious
2
Oslo University Hospital Rikshospitalet, Norwegian PSC research center, Clinic for
Specialized Medicine and Surgery, Oslo, Norway
3
University of Cologne, Clinic for Gastroenterology and Hepatology, Cologne,
Germany
Promotion of macrophage activation and inflammation in chronic liver disease by
the histidine-rich glycoprotein
Bartneck M., Fech V., Trautwein C., Tacke F.
RWTH University-Hospital Aachen, Dept. of Medicine III, Aachen, Germany
1.40
1.35
Multiple quantitative trait loci modeling (MQM) of hepatic fibrosis in a murine
intercross
Hall R. A., Lammert F.
Saarland University Medical Center, Department of Medicine II, Homburg, Germany
nd
- 20 -
WISP1 modulates immune cell infiltration upon drug-induced liver injury (DILI)
Widera A. B., Pütter L., Leserer S., Campos G., Rochlitz K., Reif R., Hammad S.,
Ghallab A. G., Marchan R., Hengstler J. G., Godoy P. G.
Technical University, IfADo-Leibniz Research Centre for Working Environment and
Human Factors, Dortmund, Germany
nd
- 21 -
1.31
1.41
Therapeutische Effekte der Modulation des Endocannabinoid-Rezeptor
Signalwegs
Helmrich N. L., Churin Y., Tschuschner A., Roderfeld M., Roeb E.
Justus-Liebig Universität, Gastroenterology, Gießen, Germany
1.42
MicroRNA-221 inhibition in hepatocytes ameliorates liver fibrosis
Tsay H.-C. 1,2,3, Yuan Q. 2,3, Balakrishnan A. 2,3, Manns M. P. 2, Ott M. 2, 3, Deep
Sharma A.1,2
1
Junior Research Group MicroRNA in Liver Regeneration, Cluster of Excellence
REBIRTH, Hannover Medical School, Hannover, Germany
2
Department of Gastroenterology, Hepatology and Endocrinology, Hannover
Medical School, Hannover, Germany
3
TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover,
Germany
1.43
MSD –
INNOVATIONEN
FÜR MENSCHEN
MIT HEPATITIS C
Über 20 Jahre Fortschritt
und Kompetenz in der
Hepatitis-C-Forschung
Role of the signaling protein Reelin in chronic liver disease and regeneration
Schindler K., Bajramovic N., Götze S., Sommerfeld A., Häussinger D., Kordes C.,
May P., Bock H. H.
University of Düsseldorf, Clinic for Gastroenterology, Hepatology and Infectiology,
1991
1999
2001
ERSTES RIBAVIRIN
ZUR HCV*-THERAPIE
IN DEUTSCHLAND
ERSTES
INTERFERON ZUR
HCV*-THERAPIE
IN DEUTSCHLAND
2011
2015
ERSTER PROTEASEINHIBITOR ZUR
HCV*-THERAPIE
IN DEUTSCHLAND
ERSTES PEGYLIERTES
INTERFERON ZUR
HCV*-THERAPIE
IN DEUTSCHLAND
* HCV = Hepatitis-C-Virus
WIR ENTWICKELN
NEUE THERAPIEN, UM
PATIENTEN
MIT CHRONISCHER
HCV*-INFEKTION
ZU HELFEN!
nd
- 22 -
MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540 Haar, www.msd.de
INFC-1143682-0000 03/15
University Medical Center Hamburg-Eppendorf, I. Medical Clinic, Hamburg,
Germany
2.1
Fibrosis regression in autoimmune hepatitis
2.5
Hartl J., Venna V., Ehlken H., Peiseler M., Sebode M., Weiler-Normann C., Zenouzi
R., Denzer U., Lohse A. W., Schramm C.
Ascites total protein may be modulated by the use of diuretics.
Lutz P.1, 2, Nischalke H. D.1, 2, Krämer B.1, 2, Langhans B.1, 2, Goeser F.1, 2,
Kaczmarek D. J.1, 2, Nattermann J.1, 2, Strassburg C. P.1, 2, Spengler U.1, 2
Hamburg, First Medical Center, Hamburg, Germany
1
2
2.2
Determining the molecular consequences of clinically relevant glutamine
synthetase mutations
2.6
Frieg B.1, Görg B.2, Homeyer N.1, Keitel V.2, Häussinger D.2, Gohlke H.1
Heinrich Heine University, Institute for Pharmaceutical and Medicinal Chemistry,
2
Heinrich Heine University, Clinic for Gastroenterology, Hepatology, and Infectious
Diseases, Düsseldorf, Germany
1
University Hospital Würzburg (UKW), Division of Hepatology, Würzburg, Germany
University Hospital Zürich (USZ), Department of Dermatology, Zürich, Swltzerland
3
University Hospital Zürich (USZ), Department of Gastroenterology and Hepatology,
Zürich, Switzerland
2
Urine cell-derived hepatocyte-like cells as potential therapeutic cell transplants
for different liver diseases
Sauer V.4, Tchaikovskaya T.1, Wang X.2, Li Y.2, Zhang W.3, Tar K.2, Polgar Z.2, Ding J.2,
Guha C.3, Fox I. J.5, Schmidt H. H.-J.4, Roy-Chowdhury N.2, Roy-Chowdhury J.2
2.7
1
Heinrich Heine Duesseldorf, Gastroenterology, Hepatology, and Infectious
2
Heinrich Heine Duesseldorf, Biological and Medical Research Center (BMFZ),
Duesseldorf, Germany
2.8
Binding Mode Prediction and Validation of Bile Acid and Neurosteroid Agonists of
TGR5
Gertzen C. G. W.1, Spomer L.2, Häussinger D.2, Keitel V.2, Gohlke H.1
Posters
2.4
Bile acid-modulated transcript-expression in human macrophages validated by
transcriptome analysis
Wammers M.1, Graf D.1, Bode J. G.1, Köhrer K.2, Deenen R.2, Häussinger D.1, Schupp
A.-K.1
1
Albert Einstein College of Medicine, Departments of Medicine and Genetics, Bronx,
New York City, United States of America
2
Albert Einstein College of Medicine, Marion Bessin Liver Research Center, Bronx,
New York City, United States of America
3
Albert Einstein College of Medicine, Departments of Radiation Oncology and
Pathology, Bronx, New York City, United States of America
4
Universitätsklinikum Münster, Klinik für Transplantationsmedizin, Münster,
Germany
5
Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center,
Department of Surgery and McGowan Institute for Regenerative Medicine,
Pittsburgh, Pennsylvania, United States of America
Beneficial effects of IL-1 cytokine inactivation and the role of the serine/threonine
kinase MK-2 in hepatic steatosis in a murine obesity model
Wohlfahrt J.1, Fettelschoss A.2, Kündig T.2, Hermanns H.1, Müllhaupt B.3, Schmitt J.1,
Geier A.1
1
2.3
Bonn, Department of Internal Medicine I, Bonn, Germany
Bonn, German Center for Infection Research, Bonn, Germany
1
Heinrich Heine University Düsseldorf, Institute for Pharmaceutical and Medicinal
Chemistry, Düsseldorf, Germany
2
Heinrich Heine University Düsseldorf, Clinic for Gastroenterology, Hepatology, and
Infectious Diseases, Düsseldorf, Germany
A pro-inflammatory role of type 2 innate lymphoid cells in murine immunemediated hepatitis
Karimi K.1, Neumann K.1, Meiners J.1, Voetlause R.1, Dammermann W.2, Lüth S.2,
Wegscheid C.1, Horst A.1, Tiegs G.1
1
nd
- 24 -
2.9
Functional role of CCL5/RANTES for HCC progression during chronic liver disease:
from humans to mice.
Mohs A.1, Kuttkat N.1, Reißing J.1, Zimmermann H. W.1, Proudfoot A.2, Youssef S. A.3,
de Bruin A.3, Cubero F. J.1, Trautwein C.1
nd
- 25 -
Clinical Hepatology
Clinical Hepatology
2
Presentations
University Hospital RWTH Aachen, Department of Internal Medicine III, Aachen,
Germany
2
Merck Serono Geneva Research Centre, Geneva, Switzerland
3
Utrecht University, Dutch Molecular Pathology Center, Department of
Pathobiology, Faculty of Veterinary Medicine, Utrecht, The Netherlands
4
University of Groningen, University Medical Center Groningen, Department of
Pediatrics, Groningen, The Netherlands
2.10
2
Medical University of Warsaw, Laboratory of Metabolic Liver Diseases, Department
of General, Transplant and Liver Surgery, Warsaw, Poland
2.13
Matz P., Wruck W., Adjaye J.
Heinrich Heine University, Medical Faculty, Institute for Stem Cell Research and
Regenerative Medicine, Duesseldorf, Germany
Changes in lipid and carbohydrate metabolism under mTOR- and calcineurinbased immunosuppressive regimen in adult patients after liver transplantation
Zimmermann A.1, Zobeley C.2, Weber M. M.1, Lang H.3, Galle P. R.2, Zimmermann T.2
2.14
1
University Medical Center Mainz, Dept. of Endocrinology and Metabolic Diseases,
1st Medical Clinic, Mainz, Germany
2
University Medical Center Mainz, Dept. of Gastroenterology and Hepatology,
Transplant Hepatology, 1st Medical Clinic, Mainz, Germany
3
University Medical Center Mainz, Dept. for General, Visceral and Transplantation
Surgery, Mainz, Germany
2.11
Combined effects of the prosteatotic TM6SF2 and PNPLA3 variants on severity of
NALFD: multicentre biopsy-based study in German patients
Der duale CCR2/CCR5 Antagonist Cenicriviroc reduziert die Infiltration proinflammatorischer CCR2+ Monozyten in Mausmodellen der akuten
Leberschädigung
Püngel T.1, Krenkel O.1, Mossanen J. C1, Ergen C.1, Liepelt A.1, Heymann F.1, Lefebvre
E.2, Trautwein C.1, Tacke F.1
1
2
2.15
Krawczyk M.1, Rau M.2, Schattenberg J.3, Bantel H.4, Pathil A.5, Demir M.6, Kluwe J.7,
Böttler T.8, Lammert F.1, Geier A.2
RWTH-University Hospital, Department of Medicine III, Aachen, Germany
Tobira Therapeutics, Inc., San Francisco, United States
Development of de novo donor-specific antibodies after liver transplantation with
antibody-mediated rejection and successful treatment by plasmapheresis
Rashidi-Alavijeh J.1, Willuweit K.1, Baba H. A.3, Paul A.2, Gerken G.1, Herzer K.1
1
University Duisburg-Essen, Department of Gastroenterology and Hepatology,
Essen, Germany
2
University Duisburg-Essen, Department of General, Visceral and Transplantation
Surgery, Essen, Germany
3
University Duisburg-Essen, Institute of Pathology, Essen, Germany
1
Saarland University Hospital, Department of Medicine II, Homburg/Saar, Germany
University Hospital Würzburg, Division of Hepatology, Department of Medicine II,
Würzburg, Germany
3
Johannes Gutenberg University, I. Department of Medicine, University Medical
Center Mainz, Mainz, Germany
4
Hannover Medical School, Department of Gastroenterology, Hepatology and
Endocrinology, Hannover, Germany
5
University of Heidelberg, Department of Internal Medicine IV, Gastroenterology
and Hepatology, Heidelberg, Germany
6
University Hospital of Cologne, Clinic for Gastroenterology and Hepatology,
Cologne, Germany
7
Hamburg University Medical Center, I. Department of Medicine, Hamburg,
Germany
8
University Hospital Freiburg, Department of Medicine II, Freiburg, Germany
2
2.12
Comparative induction of pluripotency in human umbilical vein endothelial cells
and dermal fibroblasts and further differentiation into Hepatocytes
Procholestatic gene variants and mutations in secondary sclerosing cholangitis in
critically ill patients (SC-CIP)
Jüngst C.1, Reichert M.1, Zimmer V.1, Grünhage F.1, Lammert F.1, Krawczyk M.1
2.16
Die Bedeutung des renalen Resistance-Index für das Nierenversagen nach den
neuen Kriterien bei Leberzirrhose
Herweg L.1, Herath E.2, Grotemeyer K.1, Lammert F.1, Appenrodt B.1
1
2
2.17
Saarland University, Department of Internal Medicine II, Homburg, Germany
Saarland University, Department of Internal Medicine IV, Homburg, Germany
Die Therapie mit Terlipressin und Humanalbumin ist auch bei Patienten mit
hepatorenalem Syndrom Typ 2 effektiv
Nguyen-Tat M.2, Jäger J.2, Götz E.2, Rey J. W.3, Sollinger D.1, Sivanathan V.2, Wörns
M. A.2, Schattenberg J.2, Hoffmann A.3, Galle P. R.2, Häring M.-T.2, Marquardt J. U.2
1
1
Saarland University, Department of Medicine II, Saarland University Medical
Center, Homburg, Germany
nd
- 26 -
Universitätsmedizin Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Germany
Universitätsmedizin Mainz, Cirrhose Centrum Mainz (CCM), Mainz, Germany
3
Horst-Schmidt-Kliniken Wiesbaden, Innere Medizin II, Wiesbaden, Germany
2
nd
- 27 -
Clinical Hepatology
Clinical Hepatology
1
Differential regulation of G-protein coupled bile acid receptor (Gpbar-1) by
Sp1/KLF5 family transcription factors
2.21
Treatment of chronic HCV Genotype 1 infection with Boceprevir in German reallife: The impact of SVR on initially elevated and initially normal serum alanine
aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) levels
Chintalapati C., Wöhler C., Ehlting C., Bode J., Häussinger D., Keitel V.
Buggisch P.1, Löhr H.2, Teuber G.3, Steffens H.4, Kraus M.5, Geyer P.6, Weber B.7,
Witthöft T.8, Naumann U.9, Zehnter E.10, Hartmann D.11, Dreher B.11, Bilzer M.11
Heinrich Heine University, Klinik für Gastroenterologie, Hepatologie und
Infektiologie, Düsseldorf, Germany
1
2.19
ifi Institute, Hamburg, Germany
Gastroenterological Practice, Wiesbaden, Germany
3
Gastroenterological Practice, Frankfurt, Germany
4
Practice of internal Medicine, Berlin, Germany
5
Klinium Burghausen, Medical Department II, Burghausen, Germany
6
Gastroenterological Practice, Fulda, Germany
7
Competence Center Addiction, Kassel, Germany
8
Gastroenterological Practice, Stade, Germany
9
Center of Medicine, Berlin, Germany
10
Gastroenterological Practice, Dortmund, Germany
11
MSD Pharma GmbH, Haar, Germany
Efficacy and safety of Boceprevir triple therapy in previously treated patients with
HCV Genotype 1 (G1) infection in German real-life
2
1
IFI Institute, Hamburg, Germany
3
4
5
Klinium Burghausen, Medical Department II, Burghausen, Germany
6
7
8
9
10
11
2
2.20
2.22
Pre-existing co-morbidities and co-medications of patients undergoing treatment
of chronic HCV G1 infection in German real-life
1
3
4
5
Klinium Burghausen, Burghausen, Germany
6
7
8
9
10
11
2
1
3
4
5
Klinium Burghausen, Burghausen, Germany
6
7
8
9
10
11
Boceprevir triple therapy of chronic HCV genotype 1 (G1) infection in previously
untreated patients: Efficacy, predictability of virologic response and safety in
German real-life
2
2.23
Heart rate variability and heart rate turbulence correlated with the complications
and the progress of cirrhosis and might predict the outcome of cirrhotic patients
Jansen C.1, Al-Kassou B.1, Lehmann J.1, Pohlmann A.P.1, Chang J.1, Görtzen J.1,
Nickenig G.2, Strassburg C.1, Andrié R.2, Linhart M.2, Trebicka J.1
1
2
nd
- 28 -
University of Bonn, Department of Internal Medicine II, Bonn, Germany
nd
- 29 -
Clinical Hepatology
Clinical Hepatology
2.18
Hepatitis B Reaktivierung unter Chemotherapie und Immunsuppression – eine
monozentrische Studie an 4868 Patienten
Nick E.1, Kaiser R.2, Lammert F.1, Stokes C. S.1
1
1
Saarland University Medical Center, Department of Medicine II, Homburg,
Germany
2
Saarland University Medical Center, Department of Medicine V, Homburg,
Germany
2.29
2.30
Universitätsklinikum Münster, Klinik für Transplantationsmedizin, Münster,
Germany
Improved survival in patients with primary sclerosing cholangitis and
normalization of serum cholestasis markers after biliary dilatation therapy
1
RWTH University Hospital Aachen, Internal Medicine III and Interdisciplinary Center
for Clinical Research (IZKF), Aachen, Germany
2
Medical University of Graz, Institute of Pathology, Graz, Austria
3
GH Paris-Seine-Saint-Denis, APHP, Bondy and University Paris 13, Pathology
Department, Sorbonne Paris Cité, Bobigny, France
4
Hôpital Jean Verdier, GH Paris-Seine-Saint-Denis, APHP, Centre de ressources
biologiques, Bondy, France
University Hospital Heidelberg, Internal Medicine IV, Heidelberg, Germany
In alcoholic cirrhosis, low serum hepcidin levels associate with poor long-term
survival and higher occurrence of hepatocellular carcinoma
Nuraldeen R.1, Nahon P.2, Rufat P.3, Sutton A.4, Trautwein C.1, Strnad P.1
1
RWTH University Hospital Aachen, Department of Internal Medicine III, Aachen,
Germany
2
University Paris, APHP, Liver Unit, Jean Verdier Hospital, Paris, France
3
GH Pitié-Salpêtrière, APHP, Biostatistics Unit, Paris, France
4
Bondy, and University Paris, APHP, Biochemistry Unit, Jean Verdier Hospital,
Bobigny, France
5
RWTH University Hospital Aachen, Interdisciplinary Center for Clinical Research
(IZKF), Aachen, Germany
nd
- 30 -
Keratin 23 represents a novel liver injury marker reflecting the severity of ductular
reaction
Guldiken N.1, Kobazi Ensari G.1, Lahiri P.2, Liedtke C.1, Zimmermann H. W.1,
Trautwein C.1, Ziol M.3, Strnad P.1
Rupp C., Friedrich K., Wannhoff A., Rauber C., Weiss K.-H., Stremmel W., Sauer P.,
Gotthardt D. N.
2.27
Six-month vitamin D replacement reduces hepatic steatosis in the absence of
weight loss
Papapostoli I., Lammert F., Stokes C. S.
Hepatocyte-like cell platforms for in vitro evaluation of antisense drugs in familial
amyloidosis using stem cell technology
Niemietz C., Sauer V., Stella J., Chandhok G., Zibert A., Schmidt H. H.-J.
2.26
Inadequate vitamin D levels are not associated with dietary vitamin D intake in
patients with chronic liver diseases but correlate with reduced light exposure as
quantified by actigraphy
Mielke S.1, Kreißl-Kemmer S.2, Scharbatke E. Christina3, Weiss J.2, Tony H.-P.3,
Weißbrich B.4, Geier A.2
Universität Würzburg, Medizinische Klinik und Poliklinik II, Hämatologie und
Onkologie, Würzburg, Deutschland
2
Universität Würzburg, Medizinische Klinik und Poliklinik II, Hepatologie, Würzburg,
Deutschland
3
Universität Würzburg, Medizinische Klinik und Poliklinik II,
Rheumatologie/Immunologie, Würzburg, Deutschland
4
Universität Würzburg, Institut für Virologie und Immunbiologie, Würzburg,
Deutschland
2.25
2.28
2.31
Microbubbles as used for contrast-enhanced ultrasound affect the migration of
human primary leukocytes
Warzecha K. T1, Bartneck M.1, Ehling J.2, Fokong S.2, Lammers T.2, Kiessling F.2,
Trautwein C.1, Tacke F.1
1
RWTH University Hospital Aachen, Department of Medicine III, Medical Faculty,
Aachen, Germany
2
RWTH University Hospital Aachen, Department of Experimental Molecular
Imaging, Helmholtz Institute for Biomedical Engineering, Aachen, Germany
nd
- 31 -
Clinical Hepatology
Clinical Hepatology
2.24
Natural course and prognostic factors in patients with cholestatic liver disease experience from a single center study
2.36
Comparative analysis of inflammatory biomarkers in spontaneous bacterial
peritonitis and acute-on-chronic liver failure
Stengel S. H1, Engelmann C.2, Kiehntopf M.3, Reuken P. A.1, Stallmach A.1, Berg T.2,
Bruns T.4
Adam L., Bettinger D., Thimme R., Boettler T.
University Hospital Freiburg, Department of Internal Medicine II, Freiburg, Germany
1
2.33
Jena University Hospital, Department of Internal Medicine IV (Gastroenterology,
Hepatology, and Infectious Diseases), Jena, Germany
2
University Hospital Leipzig, Section of Hepatology, Leipzig, Germany
3
Jena University Hospital, Institute of Clinical Chemistry and Laboratory Diagnostics,
Jena, Germany
4
Jena University Hospital, The Integrated Research and Treatment Center for Sepsis
Control and Care (CSCC), Jena, Germany
FUT2 variant might modulate the course in secondary sclerosing cholangitis in
critically ill patients (SC-CIP)
Reichert M. C., Jüngst C., Zimmer V., Grünhage F., Lammert F., Krawczyk M.
2.34
Prevalence and Etiology of Elevated Aminotransferases in a Cohort of Patients
referred to a German University Hospital
2.37
Marinescu A. Gabriel1, Bernsmeier A.2, Fölsch U. Robert3, Günther R.4
Ripoll C.1, Yotti R.2, Rincón D.1, Puerto M.1, Benito Y.2, Catalina M. V.1, AlhamaM.2,
Salcedo M.1, Bermejo J.2, Bañares R.1
1
National Institute of Infectious Diseases, Bucharest, Romania
University Hospital Schleswig Holstein, Campus Kiel, Departemnt of Surgery, Kiel,
Germany
3
University Hospital Schleswig Holstein, Campus Kiel, Department of Internal
Medicine, Kiel, Germany
4
University Hospital Schleswig Holstein, Campus Kiel, Department of Hepatology,
Kiel, Germany
2
2.35
Prevalence of the sphingolipid storage diseases M. Gaucher and M. Niemann-Pick
type B: results in a nation-wide screening project in 224 patients
Real Time Pressure Volume Loops in Cirrhosis: Characterization of Systolic and
Diastolic Function and Validation of Doppler Indices with the Gold Standard
1
Complutense University. Gregorio Marañón Hospital, Liver Unit. Digestive Diseases.
CIBERehd, Madrid, Spain
2
Complutense University. Gregorio Marañón Hospital, Cardiology, Madrid, Spain
3
Martin-Luther-Universität Halle-Wittenberg, Innere Medizin I, Halle (Saale),
Germany
2.38
Regenerative potential of human pluripotent stem cell-derived MSCs in a Gunn rat
liver injury model
vom Dahl S.1, Santosa D.1, Donner M.1, Merkel M.2, Vossbeck J.3, Mengel E.4,
Häussinger D.1
Spitzhorn L.-S.1, Megges M.1, Kordes C.2, Sawitza I.2, Götze S.2, Kawala M.-A.1, Wruck
W.1, Oreffo R.3, Häussinger D.2, Adjaye J.1
1
1
Heinrich-Heine-University of Duesseldorf, Dept. of Gastroenterology, Hepatology
and Infectious Diseases, Duesseldorf, Germany
2
Asklepios-Klinik Hamburg, Klinik für Allgemeine Innere Medizin, Diabetes,
Gastroenterologie, Endokrinologie und Stoffwechselerkrankungen, Hamburg,
Germany
3
Universitätsklinikum Ulm, Klinik für Kinder- und Jugendmedizin, Ulm, Germany
4
Universitätsmedizin der Johannes-Gutenberg-Universität Mainz, Zentrum für
Kinder- und Jugendmedizin, Villa Metabolica, Mainz, Germany
Heinrich Heine University Duesseldorf, Institute for Stem Cell Research and
Regenerative Medicine, Duesseldorf, Germany
2
Heinrich Heine University Duesseldorf, Clinic of Gastroenterology, Hepatology and
Infectious Diseases, Duesseldorf, Germany
3
University of Southampton, Southampton General Hospital, Southampton, United
Kingdom
2.39
Severe drug-induced liver injury related to therapy with dimethyl fumarate
Jüngst C.1, Bohle R. M.2, Lammert F.1
1
Germany
2
Saarland University Medical Center, Institute of Pathology, Homburg, Germany
nd
- 32 -
nd
- 33 -
Clinical Hepatology
Clinical Hepatology
2.32
Sicherheit und Effektivität eines getunnelten Verweilkatheters zur Aszitesdrainage
bei Patienten mit Leberzirrhose und therapierefraktärem Aszites mit
Kontraindikationen zur TIPS-Anlage
2.45
Hammel A., Wege H., Irmler P., Wehmeyer M., Werner T., Kluwe J., Lohse A. W.,
Benten D.
Genotypen-spezifische Prävalenz und Bedeutung natürlich vorkommender
Precore-, Basal Core Promotor- und preS-Mutationen in einer großen
europäischen Studienkohorte bei chronisch mit dem Hepatitis B Virus infizierten
Patienten
Sommer L.1, Peiffer K.-H.1, Dietz J.1, Susser S.1, Petersen J.2, Buggisch P.2, Cornberg
M.3, Mauss S.4, Klinker H.5, Sprinzl M. F.6, van Bömmel F.7, Hildt E.8, Berkowski C.1,
Perner D.1, Passmann S.1, Zeuzem S.1, Sarrazin C.1
Universitätsklinikum Hamburg-Ependorf, I. Medizinische Klinik, Hamburg,
Deutschland
1
2.41
Klinikum der J. W. Goethe-Universität, Medizinische Klinik 1, Frankfurt am Main,
Deutschland
2
IFI-Institut an der Asklepiosklinik St. Georg, Hamburg, Deutschland
3
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und
Endokrinologie, Hannover, Deutschland
4
Zentrum für HIV und Hepatogastroenterologie, Düsseldorf, Deutschland
5
Universitätsklinikum Würzburg, Zentrum Innere Medizin, Würzburg, Deutschland
6
Universitätsmedizin der Johannes-Gutenberg-Universität, I. Medizinische Klinik und
Poliklinik, Mainz, Deutschland
7
Universitätsklinikum Leipzig, Klinik für Gastroenterologie und Hepatologie, Leipzig,
Deutschland
8
Paul-Ehrlich-Institut, Abteilung Virologie, Langen, Deutschland
iRhom2 regulates specific activation and trafficking of TACE and enhances the
survival of TNF ɲ mediated septic shock after LPS treatment.
Maney S. M., Lang P. A.
Heinrich Heine University of Düsseldorf, Department of Gastroenterology,
Hepatology and Infectious Diseases, Düsseldorf, Germany
2.42
Spleen and liver stiffness measurement using transient elastography correlates
well with hypertensive upper gastrointestinal bleeding risk – an evaluation of 143
patients
Büchter M., Kahraman A., Manka P., Canbay A., Gerken G., Jochum C., Dechêne A.
2.46
Essen, Dept. of Gastroenterology and Hepatology, Essen, Germany
2.43
Arslanow A.1, Teutsch M.2, Walle H.2, Lammert F.1, Stokes C. S.1
Tauroursodeoxycholsäure aktiviert das Ubiquitin-Proteasom System in Hepatitis B
transgenen Zellen
1
Germany
2
Bodymed AG, Kirkel, Germany
Baier K. M., Churin Y., Schneider F., Tschuschner A., Roderfeld M., Roeb E.
Justus-Liebig-Universität Gießen, Gastroenterologie, Medizinische Klinik II, Gießen,
Deutschland
2.44
The distribution of surface antigen (HBsAg) components can distinguish between
inactive carriers and active forms of Hepatitis B virus (HBV) infections
Großmann M.1, Schott T.1, Böhm S.1, Glebe D.2, Thomas B.1, van Bömmel F.1
1
University Hospital Leipzig, Department for Gastroenterology and Rheumatology,
Hepatology Section, Leipzig, Germany
2
University Hospital Giessen, Institute for Medical Virology, Giessen, Germany
nd
- 34 -
Two week protein-enriched low-calorie diet shows rapid improvement of fatty
liver as assessed by controlled attenuation parameter
2.47
Untersuchung des Langzeitverlaufs von Patienten mit einer niedrig-replikativen
chronischen Hepatitis B-Infektion, die keine antivirale Therapie erhalten: 2 JahresDaten einer deutschen prospektiven Studie (ALBATROS Studie)
Knop V.1, Herrmann E.2, Vermehren J.1, Petersen J.3, Buggisch P.3, Wedemeyer H.4,
Cornberg M.4, Mauss S.5, Sprinzl M.6, Berg T.7, van Bömmel F.7, Klinker H.8, Hüppe
D.9, Rausch M.10, Welzel T.1, Vermehren A.1, Susser S.1, Zeuzem S.1, Sarrazin C.1
1
J.W.Goethe Universität, Medizinische Klinik 1, Frankfurt, Deutschland
J.W.Goethe Universität, Institut für Biostatistik und mathematische Modellierung,
Frankfurt, Deutschland
3
Asklepiosklinik St. Georg, IFI Institut, Hamburg, Deutschland
4
Medizinische Hochschule Hannover, Hannover, Deutschland
5
Gastroenterologische Schwerpunktpraxis, Düsseldorf, Deutschland
6
Universitätsklinik Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Deutschland
7
Universitätsklinikum Leipzig, Leipzig, Deutschland
2
nd
- 35 -
Clinical Hepatology
Clinical Hepatology
2.40
Universitätsklinikum Würzburg, Würzburg, Deutschland
Hepatologische Schwerpunktpraxis Herne, Herne, Deutschland
10
Ärztezentrum am Nollendorfplatz, Berlin, Deutschland
9
ɶ-GT is associated with splanchnic thrombotic events, CRP predicts survival in
patients with myeloproliferative neoplasms.
Autoimmunhepatitis
B
Görtzen J.1, Hunka L.1, Vonnahme M.2, Kaifie A.4, Fimmers R.3, Jansen C.1, Heine A.2,
Lehmann J.1, Brossart P.2, Strassburg C. P1, Koschmieder S.4, Wolf D.2, Trebicka J.1
Leber
Magen
1
University of Bonn, Department of Internal Medicine III, Bonn, Germany
3
University of Bonn, Department of Biometrics, Informatics and Epidemiology, Bonn,
Germany
4
RWTH Aachen University, Department of Medicine (Hematology, Oncology,
Hemostaseology, and SCT), Aachen, Germany
2
Duodenum
Colon
trans
endens
2.48
versu
m
Colon descendens
Dickdarm
Colon asc
Clinical Hepatology
Überlegene Wirksamkeit
bei Autoimmunhepatitis*
8
Jejunum
Dünndarm
inale
Term
um
s Ile
Direkt ans Ziel
Budenofalk 3mg
Budesonid
Hohe Steroid-Wirksamkeit
mit weniger Nebenwirkungen*
®
Kapseln
*im Vergleich zu systemischen Steroiden (Manns et al., Gastroenterology. 2010;139:1198-206).
nd
- 36 -
Budenofalk® 3mg Kapseln; Budenofalk® Uno 9mg Granulat; Budenofalk® Rektalschaum. Wirkstoff: Budesonid. Zusammensetzung: Eine magensaftresistente Hartkapsel Budenofalk® 3mg (= Hartkapsel mit
magensaftresistenten Pellets) enthält: Arzneil. wirks. Bestandt.: 3 mg Budesonid. 1 Beutel Budenofalk® Uno 9mg Granulat enthält: Arzneil. wirks. Bestandt.: 9 mg Budesonid. Sonstige Bestandteile Kapseln und
Beutel-Granulat: Povidon K25, Lactose-Monohydrat, Sucrose, Talkum, Maisstärke, Triethylcitrat, Methacrylsäure-Methylmethacrylat-Copolymer (1:1) (Ph.Eur.) (Eudragit L100), Methacrylsäure-MethylmethacrylatCopolymer (1:2) (Ph.Eur.) (Eudragit S100), Ammoniummethacrylat-Copolymer (Typ A) (Eudragit RL), Ammoniummethacrylat-Copolymer (Typ B) (Eudragit RS). Zusätzl. Kps.: Titandioxid (E171), gereinigtes Wasser,
Gelatine, Erythrosin (E127), Eisen(II,III)-oxide (E172), Eisen(III)-oxid (E172), Natriumdodecylsulfat. Zusätzl. Beutel-Granulat: Zitronen-Aroma. 1 Sprühstoß Budenofalk® Rektalschaum enthält: Arzneil. wirks.
Bestandt.: 2 mg Budesonid. Sonstige Bestandteile: Cetylalkohol (Ph.Eur.), Cetylstearylalkohol (Ph.Eur.), Polysorbat 60, gereinigtes Wasser, Natriumedetat (Ph.Eur.), Macrogolstearylether (Ph.Eur.), Propylenglycol,
Citronensäure-Monohydrat. Treibgase: Butan, 2-Methylpropan, Propan. Anwendungsgebiete: Budenofalk® 3mg Kps.: Akuter Morbus Crohn leichten bis mittelschweren Grades mit Beteiligung des Ileums
(Krummdarms) und/oder des Colon ascendens (Teil des Dickdarms). Kollagene Colitis. Autoimmunhepatitis. Budenofalk® Uno 9mg Granulat: Akuter Schub der kollagenen Colitis. Akuter Morbus Crohn leichten
bis mittelschweren Grades mit Beteiligung des Ileums (Krummdarms) und/oder des Colon ascendens (Teil des Dickdarms). Budenofalk® Rektalschaum: Akutbehandlung der Colitis ulcerosa, die auf das Rektum
und das Colon sigmoideum beschränkt ist. Gegenanzeigen: Überempfindlichkeit gegen Budesonid oder einen der sonstigen Bestandteile. Leberzirrhose. Schwangerschaft. Stillzeit. Kinder. Vorsicht bei: Sepsis,
Tuberkulose, Bluthochdruck, Diabetes mellitus, Osteoporose, peptischem Ulcus (Magen- oder Zwölffingerdarmgeschwür), Glaukom, Katarakt oder bei familiär gehäuft aufgetretenem Diabetes oder Glaukom.
Windpocken, Gürtelrose oder Masern. Lokale Infektionen des Darmes (Bakterien, Pilze, Amöben, Viren). Stark eingeschränkte Leberfunktion, Spätstadium einer primär biliären Zirrhose. Zusätzl. Kps. u. Granulat:
Hereditäre Galactose-Intoleranz, Fructose-Intoleranz, Lactase-Mangel, Saccharase-Isomaltase-Mangel, Glucose-Galactose-Malabsorption. Nebenwirkungen: Cushing-Syndrom: Vollmondgesicht, Stammfettsucht,
verminderte Glucosetoleranz, Diabetes mellitus, Hypertonie, Natriumretention mit Ödembildung, vermehrte Kaliumausscheidung, Inaktivität bzw. Atrophie der NNR, Striae rubrae, Steroidakne, Störung der
Sexualhormonsekretion (z. B. Amenorrhoe, Hirsutismus, Impotenz), Wachstumsverzögerung bei Kindern. Glaukom, Katarakt, Magenbeschwerden, gastroduodenales Ulcus, Pankreatitis, Verstopfung. Erhöhung des
Infektrisikos. Muskel- und Gelenkschmerzen, Muskelschwäche und -zuckungen, Osteoporose. Aseptische Knochennekrosen (Femur und Humeruskopf). Kopfschmerzen, Pseudotumor cerebri einschl. Papillenödem
bei Jugendlichen. Depressionen, Gereiztheit, Euphorie, vielfältige psychiatrische Wirkungen oder solche, die das Verhalten beeinträchtigen. Allergisches Exanthem,
Petechien, Ekchymosen, verzögerte Wundheilung, Kontaktdermatitis. Erhöhung des Thromboserisikos, Vaskulitis (Entzugssyndrom nach Langzeittherapie). Müdigkeit,
Unwohlsein. Zusätzl. Rektalschaum: Harnwegsinfektionen, Anämie, Anstieg der BSG, Leukozytose, Appetitsteigerung, Schlaflosigkeit, Schwindel, Geruchstäuschung,
Bluthochdruck, Übelkeit, Bauchschmerzen, Dyspepsie, Blähungen, Missempfindungen im Bauchbereich, Analfissur, aphthöse Stomatitis, häufiger Stuhldrang,
Hämorrhoiden, Rektalblutung, Anstieg der Transaminasen (GOT, GPT), Anstieg der Cholestaseparameter (GGT, AP), Akne, vermehrtes Schwitzen, Anstieg der Amylase,
Veränderung des Cortisols, Brennen im Enddarm und Schmerzempfindlichkeit, Asthenie, Zunahme des Körpergewichtes. Gelegentl. können NW auftreten, die typisch
für syst. wirks. Glukokortikoide sind, wobei die Häufigkeit unter Budenofalk® niedriger ist. Wechselwirkungen und Dosierung: siehe Gebrauchsinformation.
Packungsgrößen: Budenofalk® 3mg Hartkapseln: 20 (N1), 50 (N2), 100 (N3). Budenofalk® Uno 9mg Granulat: 20 Btl. (N1), 50 Btl. (N2). Budenofalk® Rektalschaum:
1 Sprühdose (N1), 2 Sprühdosen (N2). Verschreibungspflichtig.
Stand: 3/2014
Budenofalk_3mg_AIH_A4_0814.indd 1
12.08.14 10:45
3.1
Die lithogene Variante D19H im Cholsterintransporter Abcg8 führt zu
verminderter Phospholipidsekretion in Mäusen
Oenarto J.1, Karababa A.1, Castoldi M.1, Bidmon H. J.2, Görg B.1, Häussinger D.1
1
Heinrich-Heine Universität, Gastroenterologie, Hepatologie und Infektiologie,
2
Heinrich-Heine Universität, C. & O. Vogt Institut für Hirnforschung, Düsseldorf,
Deutschland
Bohner A., Rebholz C., Hall R. A, Lammert F., Weber S. N.
Universitätsklinikum des Saarlandes, Klinik für Innere Medizin II, Homburg,
Deutschland
3.2
Deficiency of the oncostatin M receptor affects the pathogenesis of non-alcoholic
fatty liver disease in a context dependent manner
3.7
3.3
Antiapoptotic and antioxidative protein ALR in Cholestatic Liver Diseases – Do bile
acids regulate ALR expression via Egr1?
Ibrahim S., Dayoub R., Melter M., Weiss T.
Hermanns H. M., Schubert S., Schäfer C., Walter S., Dorbath D., Mais C., Jahn D.,
Geier A.
Universitätsklinikum Würzburg, Med. Klinik II / Hepatologie, Würzburg, Deutschland
Ammoniak induzierte miRNA Expressionsänderungen in kultivierten
Rattenastrozyten
Regensburg, University Children Hospital, Regensburg, Germany
3.8
Development of a new modified western diet to induce NASH with obesity and
insulin resistance in mice
Arginase 1 deficiency: long-term follow-up of the original patients
Schlune A.1, vom Dahl S.1, Häussinger D.1, Ensenauer R.1, Mayatepek E.1
1
Heinrich-Heine-University Düsseldorf, Department of General Pediatrics,
Neonatology and Pediatric Cardiology, Düsseldorf, Germany
2
Heinrich-Heine-University Düsseldorf, Department of Gastroenterology,
Henkel J.1, Coleman C. D1, Jöhrens K.2, Kuna M.1, Grüner I.3, Püschel G. P.1
1
University of Potsdam, Institute of Nutrition, Department of Nutritional
Biochemistry, Nuthetal, Germany
2
Charité University Hospital Berlin, Institute of Pathology, Berlin, Germany
3
German Institute of Nutrition, Animal Facility, Nuthetal, Germany
3.9
Posters
3.4
Stindt J.1, Tiller T.2, Dröge C.1, Brackertz B.2, Kriegel C.2, Klattig J.2, Häussinger D.1,
Kubitz R.1, Keitel V.1
Ammoniak induziert NADPH-Oxidase 4- vermittelt oxidativen Stress in kultivierten
Rattenastrozyten
1
Heinrich Heine University, Department of Gastroenterology, Hepatology and
Infectious Diseases, University Hospital, Düsseldorf, Germany
2
MorphoSys AG, Martinsried, Munich, Germany
Karababa A., Aygul S., Görg B., Häussinger D.
Uniklinik Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie,
3.5
Characterization of recombinant human monoclonal antibodies against the Bile
Salt Export Pump
Ammoniak hemmt die LPS-induzierte Mikrogliaaktivierung und Transkription proinflammatorischer Zytokine in Astrozyten/Mikroglia Kokulturen
Groos-Sahr K., Albrecht U., Shafigullina A., Görg B., Häussinger D.
3.10
Deficiency of calcium-independent phospholipase A2 beta with aging causes
biliary epithelial ductular reaction associated with increased bile acids in
enterohepatic circulation
Jiao L., Gan-Schreier H., Wei W., Tuma-Kellner S., Stremmel W., Chamulitrat W.
University Heidelberg Hospital, Gastroenterology and Hepatology, Heidelberg,
Germany
Heinrich-Heine-Universität, Klinik für Gastroenterologie, Hepatologie und
Infektiologie, Düsseldorf, Deutschland
nd
- 38 -
nd
- 39 -
3.6
Presentations
Delayed intrahepatic cholestasis induced by anabolic steroids in a patient with
haploinsufficiency of the pregnane X receptor (PXR/NR1I2)
1
1
3
2
4
Liebe R. , Krawczyk M. , Raszeja-Wyszomirska J. , Kruk B. , Preis R. , Trottier J. ,
Barbier O.5, Milkiewicz P.6, Lammert F.1
1
1
2
University Hospital Aachen, Department of Medicine III and IZKF, Aachen, Germany
University of Arkansas for Medical Sciences, Arkansas Children's Hospital Research
Institute and Department of Pediatrics, Little Rock, USA
3
Medical University Graz, Institute of Pathology, Graz, Austria
4
Saarland University, Department of Pharmacy, Pharmaceutical Biology,
Saarbrücken, Germany
3.17
The power of NGS: Results from a dedicated sequencing panel of 24 genes in 40
patients with cholestatic liver disease
1
Germany
2
Grosshadern Tissue Bank and Center for Liver Cell Research, Department of
Surgery, Munich, Germany
3
University of Bern, Murtenstrasse 35, CH-3010, Department of Clinical Research,
Bern, Switzerland
4
Centre for Alcohol Research, University of Heidelberg, Department of Medicine
(Gastroenterogy), Salem Medical Centre, 69121 Heidelberg, Germany
5
Icahn School of Medicine at Mount Sinai, Department of Pharmacology and
Systems Therapeutics, New York, NY 10029, USA
Saarland University, Department of Medicine II, Homburg, Germany
Differential modulation of vesicular and non-vesicular associated microRNAs
isolated from sera of partially hepatectomized rats
Castoldi M., Kordes C., Sawitza I., Häussinger D.
3.14
3.18
Effect of paper industry leachate on various serological indices and serum proteins
Innate Immune Cell Activation in a Human in-vitro Model of Nonalcoholic
Steatohepatitis (NASH)
Riedel A.1, Hornung M.1, Schlitt H. J.1, Geissler E. K1, Werner J. M1
Khawar M. Babar, Sheikh N.
1
University of the Punjab, Q-A Campus, Cell and Molecular Biology Lab, Department
of Zoology, Lahore, 54590, Pakistan.
3.15
Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of
alcohol and cellular lipid accumulation in hepatocytes in vitro
Mahli A.1, Thasler W. E.2, Patsenker E.3, Müller S.4, Stickel F.3, Müller M.1, Seitz H.
K.4, Cederbaum A. I.5, Hellerbrand C.1
Liebe R., Krawczyk M., Zimmer V., Jüngst C., Lammert F.
3.13
Hsp72 overexpression protects from drug-induced- and lipotoxic liver injury
Levada K.1, Guldiken N.1, Vella G.1, James L. P.1, Haybaeck J.3, Kiemer A. K.4, Kessler
S. M.4, Trautwein C.1, Strnad P.1
5
Saarland University, Department of Medicine II, Homburg, Germany
2
Medical University of Warsaw, Laboratory of Metabolic Liver Diseases, Department
of General, Transplant and Liver Surgery, Warsaw, Poland
3
Medical University of Warsaw, Liver and Internal Medicine Unit, Department of
General, Transplant and Liver Surgery, Warsaw, Poland
4
Gemeinschaftspraxis für Humangenetik, DNA Diagnostik Labor, Homburg,
Germany
5
Laval University, Research Center and the Faculty of Pharmacy, Québec, Canada
6
Pomeranian Medical University, Department of Clinical and Molecular
Biochemistry, Szczecin, Poland
3.12
3.16
Hepatic gene expression profile characterizes high levels of liver regeneration
related genes in nonalcoholic fatty liver disease
3.19
University Hospital Regensburg, Department of Surgery, Regenburg, Germany
Insulin-induced cytokine production as potential contributor to hepatic insulin
resistance
Manowsky J.1, Camargo R.2, Henkel J.1, Püschel G. P1
1
Dayoub R.1, Melter M.1, Vlaic S.2, Guthke R.2, Weiss T.1
1
Regensburg, University Children Hospital Regensburg, Regensburg, Germany
Jena, Leibniz Institute for Natural Product Research and Infection Biology – HansKnöll-Institute, Jena, Germany
University of Potsdam, Nutrition Science, Nutritional Biochemistry, Nuthetal,
Germany
2
University of São Paulo (USP), Instituto de Ciências Biomédicas, São Paulo, Brazil
2
nd
- 40 -
nd
- 41 -
3.11
Kombinierte Aktivitäten von JNK1 und JNK2 in Hepatozyten schützen vor Toxininduzierten Leberschädigung
3.25
Regulation des Energiestoffwechsels in Hepatozyten durch Morphogene.
Kristin S.1, Madlen M.-S.1, Thomas M.2, Rolf G.1
1
1
1
1
1
1
Cubero F. J. , Zoubek M. E. , Hu W. , Zhao G. , Peng J. , Nevzorova Y. A. , Al
Masaoudi M.1, Bechmann L. P.2, Boekschoten M. V.3, Muller M.3, Preisinger C.4,
Gassler N.5, Canbay A. E.2, Luedde T.1, Davis R. J.6, Liedtke C.1, Trautwein C.1
1
University of Leipzig, Institute of Biochemistry, Faculty of Medicine, Leipzig,
Germany
2
Helmholtz Centre for Environmental Research - UFZ, Department of Environmental
Microbiology, Leipzig, Germany
1
University Hospital RWTH Aachen, Internal Medicine III, Aachen, Germany
University Hospital Duisburg-Essen, Department of Gastroenterology and
Hepatology, Essen, Germany
3
Wageningen University, Division of Human Nutrition, Wageningen, The
Netherlands
4
University Hospital RWTH Aachen, Proteomics Facility, Aachen, Germany
5
University Hospital RWTH Aachen, Institute of Pathology, Aachen, Germany
6
University of Massachusetts Medical School, Howard Hughes Medical Institute,
Worcester, MA, USA
2
3.21
Verlust von Caspase 8 in Leberparenchymzellen schützt vor Obstruktiver
Cholestase
3.26
Regulation of Plasma Membrane Localization of the Na+-taurocholate
cotransporting polypeptide (Ntcp) by Hyperosmolarity and
Tauroursodeoxycholate
Sommerfeld A., Mayer P. G. K., Cantore M., Häussinger D.
Heinrich-Heine University, Clinic for Gastroenterology, Hepatology and Infectious
3.27
Cubero F. J., Peng J., Hatting M., Zhao G., Zoubek M. E., Macias-Rodriguez R. U.,
Ruiz-Margain A., Reißing J., Zimmermann H. W., Gassler N., Luedde T., Liedtke C.,
Trautwein C.
Sequencing of ATP8B1, ABCB11 and ABCB4 revealed 135 genetic variants in 374
unrelated patients with suspected intrahepatic cholestasis
Dröge C., Kluge S., Häussinger D., Kubitz R., Keitel V.
University Hospital, Heinrich Heine University, Department of Gastroenterology,
University Hospital RWTH Aachen, Internal Medicine III, Aachen, Germany
3.28
3.22
Lysophosphatidylcholine (LPC) as central player for control of hepatocellular fatty
acid influx
Simvastatin senkt die hepatische Inflammation und Fibrose in Apolipoprotein E
Knock-out Mäusen nach sieben Wochen Western Diät.
Schierwagen R.1, Maybüchen L.1, Klein S.1, Uschner F. E1, Hittatiya K.2, Plat J.3,
Nickenig G.4, Strassburg C. P.1, Lütjohann D.5, Zimmer S.4, Trebicka J.1
Stremmel W., Staffer S., Wannhoff A., Pathil-Warth A., Chamulitrat W.
1
University Clinics of Heidelberg, Internal Medicine IV, Heidelberg, Germany
Universität Bonn, Medizinische Klinik und Poliklinik I, Bonn, Deutschland
Universität Bonn, Institut für Pathologie, Bonn, Deutschland
3
Universität Maastricht, Humanbiologie, Maastricht, Niederlande
4
Universität Bonn, Medizinische Klinik und Poliklinik II, Bonn, Deutschland
5
Universität Bonn, Institut für klinische Chemie und klinische Pharmakologie, Bonn,
Deutschland
2
3.23
Modelling of human nonalcoholic fatty liver disease with hepatocyte like cells
derived from pluripotent stem cells
Graffmann N., Kawala M.-A., Ring S., Wruck W., Adjaye J.
Heinrich-Heine University Düsseldorf, Institute for Stem Cell Research and
Regenerative Medicine, Düsseldorf, Germany
3.24
Nuclear ErbB2 Expression of Hepatocytes in Alcoholic Steatohepatitis as Response
to Cellular Stress Events
Döring P., Pilo G. M., Calvisi D. F., Dombrowski F.
Universitätsmedizin Greifswald, Institute of Pathology, Greifswald, Germany
nd
- 42 -
3.29
TGR5 knockout mice are highly susceptible to LCA induced liver damage
Klindt C.1, Deutschmann K.1, Reich M.1, Herebian D.2, Mayatepek E.2, Häussinger D.1,
Keitel V.1
1
Heinrich-Heine-University Düsseldorf, Clinic for Gastroenterology, Hepatology and
2
Heinrich-Heine-University Düsseldorf, Department for General Pediatrics,
Neonatology and Pediatric Cardiology, Düsseldorf, Germany
nd
- 43 -
3.20
1
IfADo-Leibniz Research Centre for Working Environment and Human Factors at the
Technical University Dortmund, Systems toxicology, Dortmund, Germany
2
Leibniz Institute for Natural Product Research and Infection Biology eV-Hans-Knöll
Institute, Jena, Germany
3
University of Regensburg Hospital, Center for Liver Cell Research, Department of
Pediatrics and Juvenile Medicine, Regensburg, Germany
4
Eberhard Karls University Tübingen, BG Trauma Center, Siegfried Weller Institut,
Tübingen, Germany
5
Charité University Medicine Berlin, Department of General-, Visceral- and
Transplantation Surgery, Berlin, Germany
6
Takara Bio Europe AB (former Cellartis AB), Gothenburg, Sweden
7
University of Edinburgh, MRC Centre for Regenerative Medicine, Edinburgh, United
Kingdom
The impact of the interaction between Embryonic stem cell-expressed Ras and
Arginase-1 in hepatic stellate cells
Nakhaeizadeh H.1, Nakhaei-Rad S.1, Amin E.1, Kordes C.2, Häussinger D.2, Ahmadian
M. R.1
1
Heinrich-Heine University, Institute of Biochemistry and Molecular Biology II,
Medical Faculty of the Heinrich-Heine University, Düsseldorf, Germany
2
Heinrich-Heine University, Hepatology and Infectious Diseases, Medical Faculty of
the Heinrich-Heine University, Düsseldorf, Germany
3.31
The liver microcirculation might be important in promoting autoimmune hepatitis
via maintaining an inflammatory cytokine milieu – A mathematical model study
Lettmann K. A.1, Hardtke-Wolenski M.2
3.36
1
Carl von Ossietzky Universität, ICBM, Oldenburg, Germany
Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology
and Endocrinology, Hannover, Germany
Up and Down of Hedgehog Signaling leads to Down and Up of Steroidogenesis in
the Liver
2
Rennert C., Matz-Soja M., Gebhardt R.
Leipzig University, Faculty of Medicine, Institute of Biochemistry, Leipzig, Germany
3.32
3.33
The liver specific microRNA-122 modulates hepatic response to infection and
inflammation by antagonizing YY1, FoxP3, Nfr1 and E2F4 molecular networks
3.37
Paluschinski M., Häussinger D., Castoldi M.
Matz-Soja M., Rennert C., Gebhardt R.
Heinrich-Heine University, Experimental Hepatology, Düsseldorf, Germany
University Leipzig, Medical Faculty, Biochemistry, Leipzig, Germany
The platelet-derived chemokine CXCL4 exerts protective role in non-alcoholic
steatohepatitis (NASH) in vivo
3.38
1
University Hospital Würzburg, Division of Hepatology, Würzburg, Germany
Purdue University, Department of Nutrition Science, West Lafayette, Indiana, USA
3
University Hospital Würzburg, Division of Nephrology, Würzburg, Germany
2
University Hospital Aachen, Department of Medicine III, Aachen, Germany
Different mouse models of oval cell induction can lead to reactivation of the
oncofetal marker Neighbor of Punc E 11.
Vitamin D Receptor Modulates Intestinal Lipid Metabolism, Adipose Tissue
Inflammation and Hepatic Steatosis in Diet-induced Obese Mice
Jahn D.1, Fleet J. C2, Kraus D.3, Schmitt J.1, Hermanns H. M1, Geier A.1
Drescher H. K., Berger C., Fischer P., Berres M.-L., Kroy D. C., Streetz K. L.,
Trautwein C., Sahin H.
3.34
Konnex von Leber und Fettgewebe via Hedgehog Signalweg?
3.39
ɲ5ɴ1 Integrins are Receptors for Bile Acids with a (Nor-)Ursodeoxycholane
Scaffold
Hoffmann V., Bowe A., Curth H. Morten, Goeser T., Nierhoff D.
University Hospital of Cologne, Clinic for gastroenterology and hepatology, Cologne,
Germany
3.35
Transcriptional regulatory networks governing stem cell differentiation into
hepatocytes in vitro
Bonus M.1, Sommerfeld A.2, Häussinger D.2, Gohlke H.1
1
Heinrich Heine University, Institute for Pharmaceutical and Medicinal Chemistry,
2
Heinrich Heine University, Clinic for Gastroenterology, Hepatology and Infectious
Diseases, Düsseldorf, Germany
Godoy P.1, Schmidt-Heck W.2, Campos G.1, Widera A.1, Stoeber R.1, Weiss T.3,
Nussler A.4, Damm G.5, Küppers-Munther B.6, Hay D. C7, Hengstler J. G.1
nd
- 44 -
nd
- 45 -
3.30
Presentations
ONE
4.1
Die Kinase RIPK1 vermittelt eine neue molekulare Interaktion zwischen
Entzündung und Zelltod in der Hepatokarzinogenese und Cholestase
Koppe C.1, Reisinger F.2, Verheugd P.3, Gautheron J.1, Roderburg C.1, Tacke F.1,
Preisinger C.4, Lüscher B.3, Vucur M.1, Trautwein C.1, Heikenwälder M.2, Luedde T.1
DER DIE WELT AUF EINE
EINFACHE FORMEL BRINGT
1
Universitätsklinikum RWTH Aachen, Medizinische Klinik III, Aachen, Deutschland
Helmholtz Zentrum München, München, Deutschland
3
Universitätsklinikum RWTH Aachen, Institut für Biochemie und Molekularbiologie,
Aachen, Deutschland
4
Universitätsklinikum RWTH Aachen, Interdisziplinäres Zentrum für Klinische
Forschung, Aachen, Deutschland
5
Deutsches Krebsforschungszentrum, Heidlelberg, Deutschland
2
HARVONI® – 1 TABLETTE / TAG a, d
4.2
Heilung bei bis zu 99 % 1–4 aller HCV GT 1-Patienten
X
X
94 %b – 99 % Heilungsrate (SVR12) bei
therapienaiven Patienten in 8 b– 24 Wochen (ION-3, ION-1)
Tautenhahn H. Michael1, Brückner S.1, Pankow F.1, Uder C.1, Brach J.1, Gittel C.3,
Hempel M.1, Berthold C.1, Lange U. Gabriele1, Broschewitz J.1, Dietel C.1, Bartels M.1,
Pietsch U. Carolin2, Christ B.1
86 % –100 % Heilungsrate (SVR12) bei
vorbehandelten Patienten in 12 – 24 c Wochen (ION-2)
1
Universitätsklinikum Leipzig, Klinik für Viszeral-, Transplantations-, Thorax- und
Gefäßchirurgie, Leipzig, Deutschland
2
Universitätsklinikum Leipzig, Klinik und Poliklinik für Anästhesiologie und
Intensivtherapie, Leipzig, Deutschland
3
Universität Leipzig, Chirurgische Tierklinik, Leipzig, Deutschland
Einfach für Arzt und Patient – 99 % Compliancee
X
X
Stammzelltherapie bei ausgedehnter Leberresektion im Schwein
Frei von Interferon , Ribavirin d und Proteaseinhibitoren
Option auf kurze 8 b-Wochen-Therapie
bei therapienaiven Patienten ohne Zirrhose
Albert Einstein, verwendet mit
Erlaubnis von HUJ / GreenLight
a HARVONI ® ist zugelassen zur Behandlung der chronischen Hepatitis C bei Erwachsenen, Fachinformation HARVONI ®, Stand Juni 2015 . b Empfohlene
Therapiedauer für therapienaive Patienten ohne Zirrhose : 12 Wochen ; eine 8-Wochen-Therapie ist bei Patienten mit einer HCV-RNA-Viruslast < 6 Mio. IU/ml in
Erwägung zu ziehen . c Es ist zu erwägen , vorbehandelte Patienten ohne Zirrhose mit ungewissen nachfolgenden Wiederbehandlungsoptionen 24 Wochen
zu behandeln . d Ausnahme: Patienten mit dekompensierter Zirrhose sowie pre- und post-transplant-Patienten erfordern die zusätzliche Gabe von
RBV. e In klinischen Studien der Phase III unter einer 12-Wochen-Therapie , ION-1 –3.
1 Afdhal N et al . N Engl J Med . 2014 ; 370 : 1889 –1898 . (ION-1) 2 Afdhal N et al . N Engl J Med . 2014 ; 370 : 1483 –1493 . (ION-2)
Med . 2014 ; 370 : 1879 –1888 . (ION-3) 4 Fachinformation HARVONI ®, Stand Juni 2015.
3 Kowdley KV et al . N Engl J
HARVONI 90 mg / 400 mg Filmtabletten
Wirkstoffe : Ledipasvir und Sofosbuvir . Zusammensetzung : Jede Filmtablette enthält 90 mg Ledipasvir und 400 mg Sofosbuvir. Sonstige Bestandteile: Tablettenkern: Copovidon, Lactose-Monohydrat, Mikrokristalline Cellulose, Croscarmellose-Natrium, Hochdisperses Siliciumdioxid, Magnesiumstearat (Ph.Eur.). Filmüberzug:
Poly(vinylalkohol), Titandioxid, Macrogol 3350, Talkum, Gelborange-S-Aluminiumsalz (E110). Anwendungsgebiet : HARVONI ® wird zur Behandlung der chronischen Hepatitis C (CHC) bei Erwachsenen angewendet (siehe Abschnitte 4.2, 4.4 und 5.1 der Fachinformation). Gegenanzeigen : Überempfindlichkeit gegen die
Wirkstoffe oder einen der sonstigen Bestandteile. Gleichzeitige Anwendung mit Rosuvastatin oder Johanniskraut (Hypericum perforatum). Nebenwirkungen :
Sehr häufig ( 1/10): Kopfschmerzen, Erschöpfung. Beschreibung ausgewählter Nebenwirkungen: Herzrhythmusstörungen. Fälle von schwerer Bradykardie und
Herzblock wurden bei der Anwendung von HARVONI® bei gleichzeitiger Anwendung von Amiodaron und/oder Arzneimitteln, die die Herzfrequenz senken, beobachtet (siehe Abschnitte 4.4 und 4.5 der Fachinformation). Darreichungsform und Packungsgrößen: Packung mit 28 Filmtabletten. Verschreibungspflichtig. Stand:
Juni 2015. Pharmazeutischer Unternehmer: Gilead Sciences International Ltd., Cambridge, CB21 6GT, Vereinigtes Königreich. Repräsentant in Deutschland:
GILEAD Sciences GmbH, D-82152 Martinsried b. München
®
4.3
Tumor infiltrating B cells producing antitumor active immunoglobulins in resected
hepatocellular carcinoma prolong patient survival
Brunner S. M.1, Itzel T.4, Rubner C.1, Kesselring R.1, Griesshammer E.1, Rümmele P.2,
Teufel A.4, Schlitt H. J. 1, Fichtner-Feigl S.1
1
University Medical Center Regensburg, Department of Surgery, Regensburg,
Germany
2
University Medical Center Regensburg, Institute of Pathology, Regensburg,
Germany
3
University Medical Center Regensburg, Regensburg Center of Interventional
Immunology, Regensburg, Germany
4
University Medical Center Regensburg, Department of Internal Medicine I,
Regensburg, Germany
Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Jeder Verdachtsfall einer Nebenwirkung zu HARVONI® ist zu melden an die Gilead Sciences GmbH,
Abteilung Arzneimittelsicherheit, Fax-Nr.: 089/899890-96, E-Mail: [email protected], und/oder an das Bundesinstitut für Arzneimittel und Medizinprodukte, Abt. Pharmakovigilanz, Kurt-Georg-Kiesinger Allee 3, D-53175 Bonn, Webseite: www.bfarm.de.
nd
- 47 -
Tumors, Liver Surgery and Transplantation
BE THE
HSK Hospital, Department of Gastroenterology, Wiesbaden, Germany
National Institutes of Health, Laboratory of Experimental Carcinogenesis, NCI/CCR,
Bethesda, MD, USA
6
German Organ Transplantation Foundation (DSO), Mainz, Germany
4.4
5
A steatotic environment promotes the progression of hepatocellular carcinoma
via direct and indirect mechanisms
Koch A.1, Mahli A.1, Lee S. M.2, Thasler W. E.2, Hartmann A.3, Müller M.1, Bosserhoff
A.-K.4, Hellerbrand C.1
4.8
Bocuk D.1, Wolff A.2, König S.1, Beißbarth T.2, Krause P.1
1
Germany
2
Ludwig-Maximilians-University Munich, Grosshadern Tissue Bank and Center for
Liver Cell Research, Department of Surgery, Munich, Germany
3
University Hospital Erlangen, Institute of Pathology, Erlangen, Germany
4
University Erlangen, Institute for Biochemistry, Biochemistry and Molecular
Medicine, Erlangen, Germany
4.5
1
Georg – August – University Göttingen, Department of General, Visceral and
Paediatric Surgery, Göttingen, Germany
2
Georg – August – University Göttingen, Statistical Bioinformatics, Department of
Medical Statistics, Göttingen, Germany
4.9
Accumulation of hepatitis B surface antigen promotes the development of alpha-1
antitrypsin mutation-related liver disease
1
1
2
2
Association of immune cell infiltration and tumor suppression in hepatocellular
carcinoma
Waldburger N., Ploeger C., Goeppert B., Schirmacher P., Roessler S.
1
University Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany
Kuscuoglu D. , Ensari G. Kobazi , Hittatiya K. , Fischer H. Peter , Trautwein C. ,
Strnad P.1
4.10
1
Expression of genes and pathways associated with colorectal liver metastases in
an orthotopic and syngeneic mouse model
University Hospital Aachen, Department of Medicine III and IZKF, Aachen, Germany
2
University Hospital Bonn, Institute of Pathology, Bonn, Germany
Autophagy impairment and ERK and p38 activation are central mediators of
irinotecan-induced steatohepatitis
Mahli A.1, Saugspier M.1, Lee S.2, Thasler W. E.2, Müller M.1, Hellerbrand C.1
4.6
Aggressive systemic mastocytosis of the liver with cholangitis
1
2
2
1
1
2
University Hospital Regensburg, Internal Medicine I, Regensburg, Germany
Großhadern Hospital, Ludwig Maximilians University, Department of Surgery,
Munich, Germany
2
3
Waldburger N. , Rupp C. , Klinke S. , Wieczorek K. , Gotthardt D. , Kirchner T. ,
Sotlar K.3, Schirmacher P.1, Straub B. K.1
1
Heidelberg University, Ruperto Carola, Institute of Pathology, Heidelberg, Germany
Heidelberg University, Ruperto Carola, Department of Internal Medicine IV,
Heidelberg, Germany
3
Ludwig-Maximilian- University Munich, Department of Pathology, Munich,
Germany
4.11
CUX1 in liver cancer: experimental study in hypoxia model
2
4.7
Analysis of transcriptomic changes during cold ischaemia in time-zero biopsies of
liver allografts
Blümel S.1, Metzger G.1, Hofmann E.1, Hänze J.2, Gress T.1, Bartsch D.3, Di Fazio P.3,
Wissniowski T.1
1
Philipps University Marburg, Department of Gastroenterology, Marburg, Germany
Philipps University Marburg, Department of Urology, Marburg, Germany
3
Philipps University Marburg, Department of Visceral, Thoracic and Vascular
Surgery, Marburg, Germany
2
Lautem A.1, Maass T.2, Krupp M.3, Rey J.4, Itzel T.2, Marquardt J.3, Thorgeirsson S. S.5,
Galle P. R.3, Barreiros A. P.6, Otto G.1, Teufel A.2
1
University Medical Center, Department of Hepatobiliary and Transplantation
2
University Medical Center, Department of Internal Medicine I, Regensburg,
Germany
3
University Medical Center, Department of Internal Medicine I, Mainz, Germany
nd
- 48 -
nd
- 49 -
4
Posters
Deregulation of the Hippo/YAP pathway drives chromosomal instability (CIN) in
hepatocellular carcinoma by regulating the transcription factor FoxM1
4.16
Weiler S.1, Pinna F.1, Lutz T.1, Wolf T.4, Roessler S.1, Wan S.1, Singer S.1, Knaub M.1,
Marquardt J.2, Lang H.3, Lee J.-S.5, Schirmacher P.1, Kalinichenko V.6, Breuhahn K.1
1
Kluge M.1, Raschzok N.1, Reutzel-Selke A.1, Napierala H.1, Hillebrandt K. H.1, Major R.
D.1, Strücker B.1, Leder A.1, Siefert J.1, Tang P.1, Lippert S.1, Sallmon H.2, Seehofer
D.1, Pratschke J.1, Sauer I. M.1
University Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany
1
Charité – Universitätsmedizin Berlin, General, Visceral, and Transplantation
Surgery, Experimental Surgery and Regenerative Medicine, Berlin, Germany
2
Charité – Universitätsmedizin Berlin, Germany, Neonatology, Berlin, Germany
2
University Medical Center Mainz, Department of Medicine I, Mainz, Germany
3
University Medical Center Mainz, Department of General, Visceral and Transplant
4
University of Heidelberg, German Cancer Consortium (DKTK) and German Cancer
Research Center (DKFZ), Heidelberg, Germany
5
University of Texas, MD Anderson Cancer Center, Houston, USA
6
University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati,
USA
4.13
4.17
1
Johannes Gutenberg University, I. Department of Medicine, Mainz, Germany
Johannes Gutenberg University, Department of Molecular Medicine, Mainz,
Germany
2
4.18
1
University Medicine Greifswald, Institute of Pathology, Greifswald, Germany
University of Regensburg, Institute of Pathology, Regensburg, Germany
3
University of Sassari, Department of Clinical and Experimental Medicine, Sassari,
Italy
2
4.14
Early ultrastructural hepatocellular alterations after hydrodynamic tail vein
injection
Ribback S.1, K. Evert2, Utpatel K.2, Annweiler K.1, Calvisi D. F1, Evert M.2, Dombrowski
F.1
1
2
4.15
Universitätsmedizin Greifswald, Institut für Pathologie, Greifswald, Germany
Universitätsklinikum Regensburg, Institut für Pathologie, Regensburg, Germany
Enhanced expression of c-myc in hepatocytes promotes initiation and progression
of alcoholic liver disease
Hepatic B cell leukemia-3 attenuates chemically-induced hepatocarcinogenesis in
mice
Gehrke N.1, Wörns M. A.1, Alt Y.1, Waisman A.2, Hoevelmeyer N.2, Galle P. R.1,
Schattenberg J. M.1
Different oncogenic potential in the mouse liver of mutant forms of the p110alpha
catalytic subunit of phosphoinositide-3-kinase (PIK3CA)
Annweiler K.1, Evert K.2, Cigliano A.1, Sini M.1, Latte G.3, Frau M.3, Pascale R. M3,
Dombrowski F.1, Calvisi D. F1, Evert M.2, Utpatel K.2
Isolation of primary human hepatocytes from human liver tissue after portal vein
embolization
Heterologous, costimulation-assisted vaccinations drive potent cellular immune
responses to cancer
Ostroumov D., Heemcke J., Manns M. Peter, Wirth T.
Medical School Hannover, Gastroenterology, Hepatology and Endocrinology,
Hannover, Germany
4.19
High levels of the soluble programmed death-ligand (sPD-L1) identify
hepatocellular carcinoma patients with a poor prognosis
Finkelmeier F.1, Canli O.2, Tal A.1, Pleli T.1, Trojan J.1, Schmidt M.1, Piiper A.1,
Kronenberger B.1, Zeuzem S.1, Greten F. R.2, Waidmann O.1
1
University Clinic Frankfurt, Gastroenterology, Frankfurt am Main, Germany
Georg-Speyer-Haus, Institute for Tumorbiology and Experimental Therapy,
Frankfurt am Main, Germany
3
Institute for Transfusion Medicine and Immunohaematology, Frankfurt am Main,
Germany
2
Nevzorova Y. A. 1, Cubero F. J.1, Hu W.1, Hao F.1, Haas U.1, Ramadori P.1, Gassler N.2,
Hoss M.3, Strnad P.1, Zimmermann H. W. 1, Tacke F.1, Trautwein C.1, Liedtke C.1
1
2
3
RWTH Aachen University, Institute of Pathology, Aachen, Germany
RWTH Aachen University, Electron Microscopic Facility, Aachen, Germany
nd
- 50 -
nd
- 51 -
4.12
5
Universitätsklinikum Bonn, Department of Genomics, Life & Brain Center, Bonn,
Deutschland
6
CCR/NCI/NIH, Laboratory of Experimental Carcinogenesis, Bethesda, USA
Identifikation neuer differenziell regulierter Mediatoren im Rahmen der
Leberregeneration
Wolf S.1, Thomas M.2, Zanger U. M2, Häussinger D.1, Bode J. G1
1
Heinrich-Heine-Universität, Klinik für Gastroenterologie, Hepatologie und
2
Robert-Bosch Krankenhaus, Dr. Margarete Fischer-Bosch-Institut für klinische
Pharmakologie, Stuttgart, Germany
4.24
Ginkgo biloba differentially affects untransformed and malignant cells in the liver
Czauderna C.1, Dominguez M. P.2, Castven D.1, Rodriguez L. Z.1, Herr M.1, Wörns
M.1, Strand S.1, Gomez-Quiroz L. E.2, Galle P. R.1, Marquardt J. U. 1
1
4.21
Universitätsmedizin Mainz, 1. Medizinische Klinik und Poliklinik, Mainz,
Deutschland
2
Universidad Autónoma Metropolitana-Iztapalapa, Departamento de Ciencias de la
Salud, Mexico City, Mexico
Identifizierung angiogener Faktoren nach Applikation von Hep3B mit
mesenchymalen Stammzellen in der immundefizienten Maus
Winkler S.1, Hempel M.1, Schmidt L.1, Ditze M.2, Böhmer F.3, Müller J.3, Kaufmann
R.2, Christ B.1
4.25
1
Universität Leipzig, Klinik und Poliklinik für Viszeral-, Transplantations-, Thoraxund Gefäßchirurgie, Angewandte Molekulare Hepatologie, 04103 Leipzig,
Deutschland
2
Friedrich-Schiller-Universität Jena, Klinik für Allgemein-, Viszeral- und
Gefäßchirurgie, 07747 Jena, Deutschland
3
Friedrich-Schiller-Universität Jena, Institut für Molekulare Zellbiologie, 07745 Jena,
Deutschland
Roy S.1, Benz F.1, Jansen J.1, Zimmermann H. W.1, Tacke F.1, Trautwein C.1,
Roderburg C.1, Luedde T.1
1
University Hospital, RWTH Aachen, Department for Gastroenterology, Digestive
Diseases and Intensive Care Medicine, Aachen, Germany
4.26
4.22
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in
mice
1
University Medicine Greifswald, Institute for Pathology, Greifswald, Germany
University of Regensburg, Institute for Pathology, Regensburg, Germany
3
University of California, 3Department of Bioengineering and Therapeutic Sciences
and Liver Center, San Francisco, USA
1
RWTH Aachen University, Department of Experimental Molecular Imaging, Aachen,
Germany
3
University Hospital Cologne, Department of Dermatology, Cologne, Germany
4
RWTH Aachen University, Institute of Molecular Pathobiochemisty, Experimental
Gene Therapy and Clinical Chemistry, Aachen, Germany
2
2
Induction of stemness features and activation of prognostically adverse genomic
alterations in hepatocellular carcinoma by field cancerization
Castven D.1, Fischer M.1, Heinrich S.2, Andersen J. B.3, Matter M.4, Sprinzl M.1,
Heilmann S.5, Wörns M.1, Thorgeirsson S. S.6, Galle P. R.1, Lang H.2, Marquardt J. U.1
1
Universitätsmedizin Mainz, 1. Medizinische Klinik und Poliklinik, Mainz,
Deutschland
2
Universitätsmedizin Mainz, Klinik für Allgemein- Viszeral- und
Transplantationschirurgie, Mainz, Deutschland
3
University of Copenhagen, BRIC, Copenhagen, Denmark
4
Universitätsspital Basel, Institut für Pathologie, Basel, Schweiz
nd
- 52 -
Molecular imaging of Cyclin E1 represents an indicator of acute and chronic liver
disease
Sonntag R.1, Heymann F.1, Mertens M.2, Rizzo L. Yokota2, Ergen C.1, Bangen J.
Martin1, Bartneck M.1, Moro N.3, Weiskirchen R.4, Kiessling F.2, Lammers T.2, Tacke
F.1, Trautwein C.1, Liedtke C.1
Calvisi D. F1, Li L.3, Pilo G. M1, Cigliano A.1, Ribback S.1, Dombrowski F.1, Chen X.3,
Evert M.2
4.23
miR-1224 is upregulated in hepatic ischemia-reperfusion injury and induces cell
death via Sp1 inhibition
4.27
Processing of MIA2 is important for its tumor suppressor function in
hepatocellular carcinoma
Solanki M.1, Hellerbrand C.2, Bosserhoff A. K1
1
2
University Erlangen, Biochemistry and Molecular Medicine, Erlangen, Germany
University Hospital Regensburg, Internal Medicine I, Regensburg, Germany
nd
- 53 -
4.20
Role of new pathways in liver regeneration after acute and chronic liver damage
4.33
The value of intraoperative White-Test for biliary leakage following hepatic
resection
Behnke K.1, Lang P.1
Linke R.1, Franz J.1, Ulrich F.1, Bechstein W. O.1, Schnitzbauer A. A.1
1
Heinrich-Heine-University, Institute of Molecular Medicine II, Duesseldorf,
Germany, NRW
4.29
1
University Hospital Frankurt, General- and Visceral Surgery, Frankfurt am Main,
Germany
Role of the bile acid receptor TGR5 (Gpbar-1) in gastrointestinal tumors
4.34
Wisp1 as an early stage marker of human hepatocellular carcinoma (HCC)?
Deutschmann K.1, Reich M.1, Krieg A.2, Knoefel W. Trudo2, Häussinger D.1, Keitel V.1
1
Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und
2
Universitätsklinikum Düsseldorf, Klinik für Allgemein-, Viszeral- und
Kinderchirurgie, Düsseldorf, Germany
4.30
Salvage in situ liver transection (ISLT) for patients with unresectable liver tumors
and insufficient volume increase of the future liver remnant after portal vein
embolization
Dropmann A.1, Feng T.1, Dediulia T.1, Ilkavets I.1, Hofmann B.1, Weng H.1, Piiper A.2,
Waidmann O.2, Quagliata L.3, Matter M.3, Dooley S.1, Meindl-Beinker N.1
1
Medical Faculty Mannheim at Heidelberg University, Mann, Molecular HepatologyAlcohol Associated Diseases, Dept. of Medicine II, Mannheim, Germany
2
University Hospital Frankfurt, Department of Medicine 1, Frankfurt, Germany
3
University Hospital Basel, Department of Molecular Pathology, Institute for
Pathology, Basel, Switzerland
Topp S. A.1, Zacarias-Föhrding L.1, Gabor I.2, Rehders A.1, Alexander A.1, Schulte am
Esch J.1, Fürst G.2, Knoefel W. T.1
1
Heinrich-Heine-University, Dept. of General, Visceral and Pediatric Surgery,
2
Heinrich-Heine-University, Dept. of Diagnostic and Interventional Radiology,
4.31
Selective targeting of tumor-associated macrophages in hepatocellular carcinoma
Kakoschky B.1, Schmithals C.1, Pleli T.1, Talab A. Atef1, Zeuzem S.1, Waidmann O.1,
Korf H.-W.2, Weigert A.3, Piiper A.1
1
University Hospital Frankfurt, Department of Medicine 1, Frankfurt am Main,
Germany
2
University Hospital Frankfurt, Institute of Anatomy 2, Frankfurt am Main, Germany
3
University Hospital Frankfurt, Institute of Biochemistry I, Frankfurt am Main,
Germany
4.32
Study of the relationship between explant histopathology and hepatocellular
carcinoma post living donor liver transplantation
Lashin A. H. 1, Elkady M. S.1, Abdelraouf H. S.1, Morsi E. A.2, Abdelbaky H. R.1, Ali M.
E.2
1
University of Benha, Hepatology, Gastroenterology & Infectious Diseases, Benha,
Egypt
2
Elsahel teaching hospital, Medicine & Gastroenterology Division, Cairo, Egypt
nd
- 54 -
nd
- 55 -
4.28
Adaptive transfer of human T cells redirected against HBV results in reduced viral
loads and induced immune responses in humanized mice
5.1
Kah J.1, Koh S.2, Volz T.1, Allweiss L.1, Lütgehetmann M.3, Bertoletti A.4, Dandri M.1
1
University Medical Center Hamburg-Eppendorf, I. Medical Department of the Center
for Internal Medicine, Hamburg, Germany
2
A*STAR, Singapore Institute for clinical Sciences, Singapore, Singapore
3
University Medical Center Hamburg-Eppendorf, Institute of Microbiology, Virology
and Hygiene, Hamburg, Germany
4
Duke-NUS Medical School, Program Emerging Infectious Diseases, Singapore,
Singapore
5
Hamburg-Lübeck-Borstel Partner Site, German Center for Infection Research,
Hamburg-Lübeck-Borstel, Germany
5.2
Induction of innate and adaptive immune responses after stopping NA therapy in
HBeAg negative chronic hepatitis B
Rinker F.1, Höner zu Siederdissen C.1, Bremer C. M2, Bremer B.1, Falk C. S3, Manns M.
P1, Wedemeyer H.1, Glebe D.2, Kraft A. RM1, Cornberg M.1
1
Hannover Medical School, Gastroenterology Hepatology and Endocrinology,
Hannover, Germany
2
Justus-Liebig-University Giessen, Institute of Medical Virology, National Reference
Center for Hepatitis B and D Viruses, Giessen, Germany
3
Hannover Medical School, Institute of Transplant Immunology, IFB-Tx, Hannover,
Germany
5.3
Kaczmarek D. J., Kokordelis P., Krämer B., Glässner A., Wolter F., Goeser F., Lutz P.,
Schwarze-Zander C., Boesecke C., Strassburg C. P., Rockstroh J. K., Spengler U.,
Nattermann J.
Unbefangen leben.
Dafür forschen wir in der Infektiologie.
Die Diagnose HIV oder Hepatitis C ändert plötzlich alles. Doch auch mit diesen
Infektionserkrankungen kann man heute ein unbefangenes Leben führen. Hepatitis C
ist sogar in den meisten Fällen heilbar.
WIR ÜBER UNS
Janssen. Mehr leben im Leben.
www.janssen-deutschland.de
Janssen-Cilag GmbH
Auf diesem Bild sind Models zu sehen. Es dient lediglich Anschauungszwecken.
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik 1, Bonn, Deutschland
Posters
ONKOLOGIE
IMMUNOLOGIE
PSYCHIATRIE / SCHMER ZTHER APIE
Als forschendes Pharmaunternehmen arbeiten wir gemeinsam mit unseren Partnern
vor Ort und weltweit daran, dass erkrankte Menschen wieder am Alltag teilhaben und
möglichst unbeschwert leben können. Wir nennen das: Mehr leben im Leben.
Charakterisierung des NK-Zellpools bei HIV/HCV-koinfizierten Patienten
INFEKTIOLOGIE
5.4
Deficiency of the B Cell-Activating Factor Receptor Results in Limited CD169+
Macrophage Function during Viral Infection
Xu H. C.1, Huang J.2, Häussinger D.1, Lang K. S.3, Lang P. A.2
1
University of Düsseldorf, Department of Gastroenterology, Hepatology and
nd
- 57 -
Viral Hepatitis and Immunology
Presentations
1
University of Düsseldorf, Department of Molecular Medicine II, Düsseldorf,
Germany
3
University of Duisburg-Essen, Institute of Immunology, Essen, Germany
5.5
Heinrich Pette Institute – Leibniz Institute for Experimental Virology, Hamburg,
Germany
2
University Medical Center Eppendorf, 1. Department of Medicine, Hamburg,
Germany
3
German Center for Infection Research (DZIF), Partner site Hamburg, Hamburg,
Germany
4
University Hospital and Medical Faculty Carl Gustav Carus, Department of Medical
Systems Biology, Dresden, Germany
Amphipathic, nucleic acid-based polymers optimized to treat hepatitis B virus
infection in patients do not harbour immune stimulatory properties in primary
isolated blood or liver cells
Broering R.1, Real C. I1, Werner M.1, Paul A.2, Gerken G.1, Vaillant A.3, Schlaak J. F.4
1
University Duisburg-Essen, University Hospital, Dept. of Gastroenterology and
2
University Duisburg-Essen, University Hospital, Dept. of General-, Visceral- and
Transplantation Surgery, Essen, Germany
3
Replicor Inc., Montreal, Quebec, Canada
4
Evangelisches Klinikum Niederrhein GmbH, Duisburg, Germany
5.10
Inhoffen J., Tuma-Kellner S., Stremmel W., Chamulitrat W.
Universitätsklinikum Heidelberg, Innnere Medizin IV, Heidelberg, Germany
5.11
5.6
Poly I:C-stimulated human non-parenchymal liver cells are potent suppressors of
hepatitis C virus replication
1
Heinrich-Heine University, Department of Gastroenterology, Hepatology and
Infectious Diseases, Duesseldorf, Germany
2
Heinrich-Heine University, Department of Dermatology, Duesseldorf, Germany
3
Heinrich-Heine University, Institute for Virology, Duesseldorf, Germany
1
5.7
Diminished Antiviral Cytokine Response in Bile Duct Ligated Mice
Schupp A.-K.1, Kislat A.2, Homey B.2, Häussinger D.1, Zimmermann A.3, Graf D.1,
Rattay S.3
Werner M.1, Lukowski K.1, Paul A.2, Gerken G.1, Schlaak J. F3, Broering R.1
University Duisburg-Essen, University Hospital, Dept. of Gastroenterology and
2
University Duisburg-Essen, University Hospital, Dept. of General-, Visceral- and
Transplantation Surgery, Essen, Germany
3
Evangelisches Klinikum Niederrhein GmbH, Duisburg, Germany
Deficiency of Group VIA phospholipase A2 Primes the Cytokine Releases by
Kupffer cells and Lymphocytes
5.12
HCV-specific immune responses under direct-acting antiviral therapy of chronic
HCV infection
Characterization and functional modulation of HBV-specific CD4+ T cell responses
Dembek C.1, Russo C.1, Grambihler A.5, Schattenberg J.5, Zimmermann T.5, Bauer T.1,
Weinmann A.5, Galle P. R5, Protzer U.4, Sprinzl M. F5
Jacobi F., Flecken T., Thimme R., Boettler T.
University Hospital Freiburg, Department of Medicine II, Freiburg, Germany
1
Helmholtz Zentrum München, Institute of Virology, Munich, Germany
Helmholtz Zentrum München, Cooperation Group ‘Immune Monitoring’, Munich,
Germany
3
German Center for Infection Research (DZIF), Munich, Germany
4
Technische Universität München, Institute of Virology, Munich, Germany
5
University Medical Center, 1st Medical Department, Mainz, Germany
2
5.8
Comparative analysis of CD1d-restricted natural killer T cells in people who inject
drugs with chronic or spontaneously resolved hepatitis C
Senff T.1, Thöns C.1, Scherbaum N.2, Timm J.1
1
University Hospital Düsseldorf, Heinrich-Heine-University, Institute for Virology,
2
Rhine State Hospital, Hospital of the University of Duisburg-Essen, Department of
Psychiatry and Psychotherapy, Addiction Research Group, Essen, Germany
5.9
CRISPR/Cas9 “double”-nickase mediated inactivation of hepatitis B virus
replication
Karimova M.1, Beschorner N.1, Dammermann W.2, Chemnitz J.1, Indenbirken D.1,
Grundhoff A.1, Lüth S.2, Buchholz F.4, Schulze zur Wiesch J.2, Hauber J.1
nd
- 58 -
5.13
Hepatitis C virus inhibits IL-1ɴ-induced IʃBɺ expression in a Calpain- and MK2dependent manner resulting in LCN2 suppression
Stindt S.1, Spitzley S.1, Bartenschlager R.2, Häussinger D.1, Bode J. G.1
1
Infectious Diseases, University Hospital, Düsseldorf, Germany
2
Heidelberg University, Department for Infectious Diseases, Molecular Virology,
Heidelberg, Germany
nd
- 59 -
2
Division of Virus-Associated Carcinogenesis, German Cancer Research Center
(DKFZ), Heidelberg, Germany
5.14
5.18
Knodel M. M.1, Nägel A.1, Reiter S.1, Rupp M.1, Vogel A.1, Targett-Adams P.2,
McLauchlan J.3, Herrmann E.4, Wittum G.1
HIV Mono-Infektion ist mit gestörter Anti-HCV-Aktivität von NK-Zellen assoziiert
1
Goethe-Universität Frankfurt, Goethe Center for Scientific Computing, Frankfurt,
Germany
2
Medivir AB, Huddinge, Sweden
3
MRC-University of Glasgow, Centre for Virus Research, Glasgow, United Kingdom
4
Goethe-Universität Frankfurt, Department of Medicine, Frankfurt, Germany
Goeser F., Glässner A., Kokordelis P., Wolter F., Lutz P., Kaczmarek D. J., SchwarzeZander C., Boesecke C., Strassburg C. P., Rockstroh J. K., Spengler U., Krämer B.,
Nattermann J.
University Clinic Bonn, Department of Internal Medicine I & German Center for
Infection Research (DZIF), Bonn, Germany
5.19
5.15
IFN-mediated cytokine induction is associated with sustained virological response
in chronic HCV infection
1
2
1
3
Wandrer F. , Falk C. , Manns M. P. , Schulze-Osthoff K. , Bantel H.
1
5.16
1
2
5.20
IL-12 rather than immune checkpoint inhibitors contribute to the functional
restoration of hepatitis D virus-specific T-cells
Schirdewahn T., Grabowski J., Sekyere S. O., Bremer B., Wranke A., Lunemann S.,
Schlaphoff V., Kirschner J., Hardtke S., Manns M. P., Cornberg M., Wedemeyer H.,
Suneetha P. V.
1
University Medical Center Hamburg-Eppendorf, Hamburg, I. Department of
Internal Medicine, Hamburg, Germany
2
Justus-Liebig University Giessen, Institute of Medical Virology, Gießen, Germany
3
Asklepios Clinic St. Georg, Hamburg, Germany
4
University Medical Center Hamburg-Eppendorf, Institute of Microbiology, Virology
and Hygiene, Hamburg, Germany
nd
- 60 -
Quantification of serum HBV RNA allows differentiation of disease stages of
hepatitis B virus (HBV) infections
University Clinic Leipzig, Clinic for Gastroenterology and Rheumatology, Hepatology
Section, Leipzig, Germany
5.21
Redundant tolerance mechanisms prevent autoimmune liver inflammation in
mice
Leypoldt L., Laschtowitz A., Schramm C., Huber S., Lohse A. W., Carambia A., Herkel
J.
Lack of HBeAg does not induce stronger enhancement of innate immunity genes
in humanized mice
Luft S.1, Bremer C. M2, Volz T.1, Seiz P. L2, Allweiss L.1, Giersch K.1, Petersen J.3, Lohse
A. W1, Lütgehetmann M.4, Glebe D.2, Dandri M.1
Universitätsklinikum Bonn, Medizinischen Klinik und Poliklinik I, Bonn, Deutschland
Deutsches Zentrum für Infektionsforschung, Bonn-Köln, Bonn, Deutschland
Krauel A., Böhm S., Maria G., Deichsel D., Berg T., van Bömmel F.
Hannover Medical School, Gastroenterology, Hepatology and Endocrinology,
Hannover, Germany
5.17
Assoziation des IL28B Polymorphismus mit dem Ausmaß der Monozyteninduzierten NK Zell-Aktivierung bei der Hepatitis C
Krämer B.1, Finnemann C.1, Sastre Turrión B.1, Wolter F.1, Glässner A.1, Kokordelis
P.1, Philipp L.1, Goeser F.1, Kaczmarek D.1, Nischalke H. D.1, Langhans B.1, Strassburg
C. P.1, Spengler U.1, Nattermann J.1
1
Hannover Medical School, Dept. of Gastroenterology, Hepatology and
Endocrinology, Hannover, Germany
2
Hannover Medical School, Institute of Transplant Immunology, IFB-Tx, Hannover,
Germany
3
University of Tuebingen, Interfaculty Institute for Biochemistry, Tuebingen,
Germany
Mechanistic dynamics of Hepatitis C virus replication in single liver cells
University Medical Center Hamburg-Eppendorf, Department of Medicine I,
Hamburg, Germany
5.22
The breadth of CD8+ T cell responses in chronic and resolved HBV infection
Ehrenmann P. S., Kiraithe M. M., Lang J. K., Jacobi F. J., Thimme R., NeumannHaefelin C.
University Hospital Freiburg, Department of Internal Medicine II, Freiburg, Germany
nd
- 61 -
3
The diverse functions of transcription factors in T cell immunity during LCMV
infection
Grusdat M. Denise, Lang P. A.
Heinrich-Heine- Universität, Institut für molekulare Medizin II, Düsseldorf, Germany
5.24
The Hepatitis C Virus (HCV) results in an increased attraction of human
neutrophils to its host cell by a basal and EGF-induced CXCR2 ligand expression
Gröpper C.1, Bartenschlager R.2, Häussinger D.1, Bode J. G1
1
Universityhospital, Heinrich-Heine University Düsseldorf, Department for
Gastroenterology, Hepatology and Infectious Diseases, Düsseldorf, Germany
2
Heidelberg University, Department for Infectious Diseases, Molecular Virology,
Division of Virus-Associated Carcinogenesis, German Cancer Research Cent,
Heidelberg, Germany
5.25
The HLA-DPA1 rs3077 TT polymorphism is associated with spontaneous resolution
of hepatitis B virus (HBV) infections in Caucasians
Koukoulioti E., Fischer J., Boehm S., Berg T., van Bömmel F.
University of Leipzig, Gastroenterology and Rheumatology, Leipzig, Germany
13186
5.23
ERWARTEN SIE MEHR
Erweitern Sie Ihre Möglichkeiten für mehr Effizienz in der ERCP.
Das V-System bietet Ihnen größtmögliche Flexibilität
In Kombination mit dem revolutionären Führungsdraht VisiGlide und einem vielseitigen
Sortiment von Endo-Therapie-Instrumenten ist das V-System die ideale Lösung für einfache und
schnelle Prozeduren. Es vereinfacht Instrumentenwechsel und ist dabei mit langen und kurzen
Führungsdrähten kompatibel. Das V-System bietet Ihnen größtmögliche Flexibilität!
Mehr Information erhalten Sie unter www.olympus.de
nd
- 62 Medical Systems, Wendenstraße 14–18, 20097 Hamburg, Germany | Tel.: 0800 200 444 212 | www.olympus.de
GASL Presidents
1985-2016
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
GASL Secretaries
1985-2016
K.-H. Meyer zum Büschenfelde, Mainz
K. Jungermann, Göttingen
R. Pichlmayr, Hannover
I. Roots, Berlin
G. Strohmeyer, Düsseldorf
U. Pfeifer, Bonn
W. Gerok, Freiburg
A. M. Gressner, Marburg
P. Neuhaus, Berlin
D. Keppler, Heidelberg
G. Paumgartner, München
C. Broelsch, Hamburg
A. Wendel, Konstanz
W.E. Fleig, Halle/Saale
B. Kremer, Kiel
H.P. Dienes, Köln
S. Matern, Aachen
J. Hauss, Leipzig
W. Reutter, Berlin
H.E. Blum, Freiburg
C. Henne-Bruns, Ulm
R. Gebhardt, Leipzig
G. Ramadori, Göttingen
W.O. Bechstein, Frankfurt am Main
P. Schirmacher, Heidelberg
T. Sauerbruch, Bonn
H.J. Schlitt, Regensburg
G. Tiegs, Hamburg
M.P. Manns, Hannover
A. Königsrainer, Tübingen
U. Protzer, München
D. Häussinger, Düsseldorf
1985-1988
1989-1991
1992-1994
1995-1997
1998-2000
2001-2003
2004-2006
2007-2009
2010-2012
2013-2015
2016-2018
Location
E.G. Hahn
M. Manns
W.E. Fleig
A. Holstege
G. Gerken
G. Tiegs
A.W. Lohse
E. Roeb
R. Thimme
J. Nattermann
V. Keitel
Venue
Building 23.01
Lecture hall 3D and foyer
40225 Düsseldorf
Link to map of campus
Arriving by car:
From the east the university is best reached from Hildener Kreuz (A 3/ A 46) via DüsseldorfSüd junction (A 46). Leave the A 46 in the tunnel (exit Zentrum/ Universität). Turn left at
the first traffic lights into Universitätsstraße which runs through the campus.
From the west the university is best reached from Neuss-Süd junction where the A 46 and
A 57 merge. After the Fleher Rhine bridge take the exit Bilk/ Zentrum/ Hafen/ Benrath.
Stay in the right-hand lane and follow the signs to Benrath/ Universität.
Arriving by public transport:
Düsseldorf main station is connected to all international long-distance train routes. Both
the U79 and the 707 tram go from there directly to the university (Uni-Ost / Botanischer
Garten)
The university is also on the route of the following busses: 735, 827, 835 and 836.
nd
- 64 -
nd
- 65 -
! "
#$ %
,$ &
.
1
(&
2
3
2
(
*
'
%
2
)
&& "
&4 6 7 ). 89)999:1
/
;
.
)<99:1 $ ' $
)*) <)999:1
)<99:1 ?
7
&4 8)999:1
"
6"
" $
A
3
*
nd
- 66 -
& '
$
.
(
.
)*)+
/
&
*
) 0 '(
*
) "
(&
45
&4 <)999:1 3
&4 <)999:1 >
&4 )<99:1 @
&
= &&
"
&4 <)999:1
&
$
;
&4 6 7 )
&4
.
/)
The 33rd Annual Meeting of GASL in Essen
GASL President 2017
Prof. Dr. med. Guido Gerken
Klinik für Gastroenterologie und Hepatologie
Medizinisches Zentrum
Universitätsklinikum Essen
Hufelandstr. 55
D-45147 Essen
Essen, Katernberg, St. Joseph © Steffen Schmitz commons.wikimedia.org
Imprint
Responsible for scientific organisation:
on behalf of Universitätsklinikum Düsseldorf
Clinic for Gastroenterology, Hepatology and
Infectious Diseases
Moorenstraße 5
40225 Düsseldorf
Responsible for editorial contents:
Infectious Diseases
Moorenstr.5, 40225 Düsseldorf
Congress organisation:
Conventus Congressmanagement
& Marketing GmbH
Carl-Pulfrich-Str. 1
07745 Jena
nd
- 68 -
Index
A
Abdelbaky H. R. 54
Abdelraouf H. S. 54
Abramovic K. 19
Adam L. 32
Adjaye J. 27, 33, 42
Ahmadian R. 17, 44
Al Masaoudi M. 42
Albrecht U. 13, 15, 38
Alexander A. 54
Alhama M. 33
Ali M. 54
Al-Kassou B. 29
Allweiss L. 57, 60
Alt Y. 51
Amin E. 44
Andersen J. B. 52
Andrié R. 29
Annweiler K. 50
Appenrodt B. 27
Arslanow A. 35
Asimakopoulou A. 18
Augustin H. 19
Aygul S. 38
B
Baba H. A. 27
Baier K. M. 15, 34
Bajramovic N. 22
Balakrishnan A. 22
Bañares R. 33
Bangen J. M. 10, 13, 20, 53
Bantel H. 26, 60
Barbier O. 40
Barikbin R. 14
Barreiros A. P. 48
Bartels M. 47
Bartenschlager R. 59, 62
Bartneck M. 20, 31, 53
Bartsch D. 49
Bauer T. 59
Bechmann L. P. 42
Bechstein W. O. 55, 64
Behnke K. 54
Beißbarth T. 49
Benito Y. 33
Benten D. 34
Benz F. 16, 17, 53
Berg T. 33, 35, 61, 62
Berger C. 44
Berger T. 18
Berkowski C. 35
Bermejo J. 33
Bernsmeier A. 32
Berres M.-L. 44
Berthold C. 47
Bertoletti A. 57
Beschorner N. 58
Bettinger D. 32
Beuke K. 13
Bidmon H. J. 39
Bierwolf J. 16
Bilzer M. 28, 29
Bissinger M. 13
Blümel S. 49
Boaru S. G. 19
Bock H. H. 22
Bocuk D. 49
Bode J. 13, 15, 25, 28, 52,
59, 62
Boehm S. 62
Boekschoten M. V. 42
Boesecke C. 57, 60
Boettler T. 32, 58
Bohle R. M. 33
Böhm S. 34, 61
Böhmer F. 52
Bohner A. 38
Bonus M. 45
Borkham-Kamphorst E. 18,
19, 20
Bosserhoff A.-K. 48, 53
Böttler T. 26
Bowe A. 15, 44
Brach J. 47
Brackertz B. 39
Brandenburg L.-O. 17
Breitkopf-Heinlein K. 19
Bremer B. 57, 60
Bremer C. M. 60
Breuhahn K. 13, 50
Broering R. 58
Broschewitz J. 47
nd
Brossart P. 36
Brückner S. 47
Brunner S. M. 47
Bruns T. 33
Buchholz F. 58
Büchter M. 34
Buggisch P. 28, 29, 35
C
Calvisi D. F. 42, 50, 52
Camargo R. 41
Campos G. 15, 18, 21, 44
Canbay A. 34, 42
Canli O. 51
Cantore M. 43
Carambia A. 14, 61
Castoldi M. 39, 40, 44
Castven D. 52, 53
Catalina M. V. 33
Cederbaum A. I. 41
Chalupsky K. 14
Chamulitrat W. 21, 39, 42,
59
Chandhok G. 30
Chang J. 29
Chemnitz J. 58
Chen S. 19
Chen X. 52
Chintalapati C. 28
Christ B. 47, 52
Churin Y. 15, 22, 34
Cigliano A. 50, 52
Coleman C. D. 38
Cornberg M. 35, 57, 60
Cubero F. J. 25, 42, 50
Curth H. M. 15, 44
Czauderna C. 53
E
Ebert M. 19
Ehling J. 31
Ehlken H. 24
Ehlting C. 15, 28
Ehrenmann P. S. 61
Elkady M. S. 54
Engel B. 14
Engelmann C. 33
Ensenauer R. 39
Ergen C. 27, 53
Evert K. 50
Evert M. 50, 52
D
F
Dahmen U. 15
Damm G. 44
Dammermann W. 24, 58
Dandri M. 57, 60
Davis R. J. 42
Dayoub R. 39, 40
de Bruin A. 25
Dechêne A. 34
Falk C. 57, 60
Fech V. 20
Feng T. 55
Fettelschoss A. 25
Feuer R. 15
Fichtner-Feigl S. 47
Fickert P. 15
Fimmers R. 36
- 70 -
Dediulia T. 55
Deenen R. 15, 25
Deep Sharma A. 22
Deichsel D. 61
Dembek C. 59
Demir M. 26
Denzer U. 24
Deutschmann K. 43, 54
Dewidar B. 16
Di Fazio P. 49
Dietel C. 47
Dietz J. 35
Ding J. 24
Ditze M. 52
Dombrowski F. 42, 50, 52
Dominguez M. P. 53
Donner M. 32
Dooley S. 13, 16, 19, 55
Dorbath D. 38
Döring P. 42
Dorn C. 19
Dreher B. 28, 29
Drescher H. K. 44
Dröge C. 39, 43
Dropmann A. 55
Finkelmeier F. 51
Finnemann C. 61
Fischer H. P. 48
Fischer J. 62
Fischer M. 52
Fischer P. 44
Flecken T. 58
Fleet J. C. 45
Fokong S. 31
Fölsch U. R. 32
Fox I. J. 24
Franz J. 55
Frau M. 50
Freese K. 19
Friedrich K. 30
Frieg B. 24
Fülöp A. 18
Fürst G. 54
G
Gabor I. 54
Gaestel M. 15
Gaitantzi H. 19
Galle P. R. 26, 27, 48, 51,
52, 53, 59
Gan-Schreier H. 21, 39
Gassler N. 18, 42, 50
Gautheron J. 47
Gebauer S. 14
Gebhardt R. 45
Gehrke N. 51
Geier A. 25, 26, 30, 38, 45
Geissler E. K. 41
Gekle M. 18
Gerken G. 27, 34, 58
Gertzen C. G. 25
Geyer P. 28, 29
Ghallab A. 13, 18, 21
Giebeler A. 17
Giersch K. 60
Gittel C. 47
Glaser F. 14
Glässner A. 57, 60, 61
Glebe D. 34, 57, 60
Godoy P 15, 18, 21, 44
Goeppert B. 49
Goeser F. 25, 57, 60, 61
Goeser T. 44
Gohlke H. 24, 25, 45
nd
Gomez-Quiroz L. E. 53
Görg B. 24, 38, 39
Görtzen J. 16, 29, 36
Gotthardt D. 30, 48
Götz E. 27
Götze S. 15, 17, 22, 33
Grabowski J. 60
Graf D. 25, 59
Graffmann N. 42
Grambihler A. 59
Greinert R. 16
Gress T. 49
Greten F. R. 51
Griesshammer E. 47
Groos-Sahr K. 38
Gröpper C. 62
Großmann M. 34
Grotemeyer K. 27
Grundhoff A. 58
Grüner I. 38
Grünhage F. 26, 32
Grusdat M. 62
Guha C. 24
Guldiken N. 31, 41
Günther R. 32
Guthke R. 40
H
Haas U. 20, 50
Hall R. A. 20, 38
Hammad S. 21
Hammel A. 34
Hammer S. 18
Hammerich L. 13
Hänze J. 49
Hao F. 50
Hardtke S. 60
Hardtke-Wolenski M. 44
Häring M.-T. 27
Hartl J. 24
Hartmann A. 48
Hartmann D. 28, 29
Hassan R. 13
Hatting M. 42
Hauber J. 58
Häussinger D. 15, 17, 21, 22,
24, 25, 28, 32, 33, 38, 39,
40, 43, 44, 45, 52, 54, 57,
59, 62
- 71 -
Hay D. C. 44
Haybaeck J. 41
Heemcke J. 51
Heeren J. 14
Heikenwälder M. 47
Heilmann S. 52
Heine A. 36
Heinrich S. 52
Hellerbrand C. 19, 41, 48,
49, 53
Helmrich N. L. 22
Hempel M. 47, 52
Hengstler J. 13, 15, 18, 21,
44
Henkel C. 18
Henkel J. 38, 41
Herath E. 27
Herebian D. 43
Herkel J. 14, 61
Hermanns H. 25, 38, 45
Herr M. 53
Herrmann E. 35, 61
Herweg L. 27
Herzer K. 27
Heymann F. 27, 53
Hildt E. 35
Hillebrandt K. H. 51
Hittatiya K. 43, 48
Hoevelmeyer N. 51
Hoffmann A. 27
Hoffmann V. 15, 44
Hofmann B. 55
Hofmann E. 49
Höhne J. 21
Hollenbach M. 16
Homey B. 59
Homeyer N. 24
Höner zu Siederdissen C. 57
Hopf C. 18
Hornung M. 41
Horst A. 19, 24
Hoss M. 50
Hov J. 21
Hu W. 42, 50
Huang J. 57
Huber M. 20
Huber S. 61
Hunka L. 36
Hüppe D. 35
Huynh K. C. 20, 21
I
Ibrahim S. 39
Ilkavets I. 55
Indenbirken D. 58
Inhoffen J. 59
Irmler P. 34
Itzel T. 17, 47, 48
J
Jacobi F. 58, 61
Jäger J. 27
Jahn D. 38, 45
James L. P. 41
Jansen C. 29, 36
Jansen J. 53
Jiao L. 39
Jochum C. 34
John C. 14
Jöhrens K. 38
Jouy F. 14
Jüngst C. 26, 32, 33, 40
K
Kiraithe M. 61
Kirchner T. 48
Kirschner J. 60
Kislat A. 59
Klattig J. 39
Klein S. 13, 16, 43
Klindt C. 43
Klinke S. 48
Klinker H. 35
Kluge M. 51
Kluge S. 43
Kluwe J. 26, 34
Knaub M. 50
Knodel M. 61
Knoefel W. T. 54
Knolle P. 13
Knop V. 35
Kobazi G. 31, 48
Koch A. 48
Koh S. 57
Köhn-Gaone J. 14
Köhrer K. 15, 25
Kokordelis P. 57, 60, 61
König C. 19
König S. 49
Koppe C. 47
Köppel A. 15
Kordes C. 15, 17, 22, 33, 40,
44
Korf H.-W. 54
Koschmieder S. 36
Koukoulioti E. 62
Kraft A. 57
Krämer B. 25, 57, 60, 61
Krauel A. 61
Kraus D. 45
Kraus M. 28, 29
Krause P. 49
Krawczyk M. 26, 32, 40
Krech T. 14
Kreißl-Kemmer S. 30
Krenkel O. 27
Krieg A. 54
Kriegel C. 39
Kristin S. 43
Kronenberger B. 51
Kroy D. C. 44
Kruk B. 40
Krupp M. 48
Kaczmarek D. J. 11, 25, 57,
60, 61
Kah J. 57
Kahraman A. 34
Kaifie A. 36
Kaiser R. 31
Kakoschky B. 54
Kalinichenko V. 50
Kalkhof S. 14
Kanzler S. 17
Karababa A. 38, 39
Karimi K. 18, 24
Karimova M. 58
Karlsen T. 21
Kaufmann R. 52
Kawala M.A. 33, 42
Keitel V. 21, 24, 25, 28, 39,
43, 54
Kesselring R. 47
Kessler S. M. 41
Khawar M. B. 40
Kiehntopf M. 33
Kiemer A. K. 41
Kiessling F. 31, 53
nd
- 72 -
Kubitz R. 39, 43
Kummer U. 13
Kuna M. 38
Kündig T. 25
Küppers-Munther B. 44
Kuscuoglu D. 48
Kuttkat N. 25
L
Lahiri P. 31
Laleman W. 16
Lambertz J. 19
Lammers T. 31, 53
Lammert F. 20, 26, 27, 31,
32, 33, 35, 38, 40
Lang H. 26, 50, 52
Lang J. K. 61
Lang K. S. 57
Lang P. A. 34, 54, 57, 62
Lange U. G. 47
Langhans B. 25, 61
Laschtowitz A. 61
Lashin A. H. 54
Latte G. 50
Lautem A. 48
Leder A. 51
Lee J. S. 50
Lee S. 48, 49
Lefebvre E. 27
Lehmann J. 29, 36
Leserer S. 18, 21
Lettmann K. A. 44
Levada K. 41
Leypoldt L. 61
Li L. 52
Li Y. 16, 24
Liebe R. 13, 19, 40
Liedtke C. 13, 20, 31, 42,
50, 53
Liepelt A. 27
Linhart M. 29
Linke R. 55
Lippert S. 51
Löhr H. 28, 29
Lohse A. W. 14, 24, 34, 60,
61, 64
Luch A. 14
Luedde T. 16, 17, 42, 47, 53
Luft S. 60
Lukowski K. 58
Lüllmann-Rauch R. 14
Lunemann S. 60
Lüscher B. 47
Lütgehetmann M. 57, 60
Lüth S. 24, 58
Lütjohann D. 43
Lutz P. 25, 57, 60
Lutz T. 50
Mohs A. 25
Moro N. 53
Morsi E. A. 54
Mossanen J. C. 27
Müller A. 19
Müller J. 52
Muller M. 42
Müller M. 14, 19, 41, 48, 49
Müller S. 41
Müllhaupt B. 25
M
Maass T. 17, 48
Macias-Rodriguez R. U. 42
Madlen M.S. 43
Mahli A. 41, 48, 49
Mais C. 38
Major R. D. 51
Mak T. W. 18
Maney S. M. 34
Manka P. 34
Manns M. P. 22, 51, 57, 60
Manowsky J. 41
Marchan R. 21
Maria G. 61
Marinescu A. G. 32
Marquardt J. 27, 48, 50, 52,
53
Matter M. 52, 55
Matz P. 27
MatzSoja M. 45
Mauss S. 35
May P. 22
Mayatepek E. 39, 43
Maybüchen L. 43
Mayer P. G. 43
McLauchlan J. 61
Megges M. 33
Meindl-Beinker N. 55
Meiners J. 24
Melter M. 39, 40
Mengel E. 32
Merkel M. 32
Mertens M. 53
Metzger G. 49
Meurer S. K. 19, 20
Meyer C. 19
Michl P. 16
Mielke S. 30
Milkiewicz P. 40
N
Nägel A. 61
Nahon P. 30
Nakhaei-Rad S. 17, 44
Nakhaeizadeh H. 17, 44
Napierala H. 51
Nattermann J. 25, 57, 60, 61
Naumann U. 28, 29
Neß M. 19, 20
Neumann K. 18, 24
Neumann U. 16, 17
Neumann-Haefelin C. 61
Nevzorova Y. A. 42, 50
Nguyen H. 20, 21
NguyenTat M. 27
Nick E. 31
Nickenig G. 29, 43
Niemietz C. 30
Nierhoff D. 15, 21, 44
Nischalke H. D. 25, 61
Nuraldeen R. 30
Nussler A. 44
O
Oenarto J. 39
Oreffo R. 33
Ostroumov D. 51
Ott M. 22
Otto G. 48
P
Paluschinski M. 44
Pankow F. 47
Papapostoli I. 31
Pascale R. M. 50
Passmann S. 35
Pathil A. 21, 26
Pathil-Warth A. 42
nd
- 73 -
Patsenker E. 41
Paul A. 27, 58
Peiffer K.-H. 35
Peiseler M. 24
Peng J. 42
Perner D. 35
Petersen J. 35, 60
Pfaff M. 18
Philipp L. 61
Pietsch U. C. 47
Piiper A. 51, 54, 55
Pilo G. M. 42, 52
Pinna F. 13, 50
Plat J. 43
Pleli T. 51, 54
Ploeger C. 49
Pohl S. 16, 18
Pohlmann A.-P. 29
Polgar Z. 24
Pollok J. M. 16
Pratschke J. 51
Preis R. 40
Preisinger C. 42, 47
Protzer U. 59
Proudfoot A. 25
Puerto M. 33
Püngel T. 27
Püschel G. P. 38, 41
Pütter L. 15, 18, 21
Reißing J. 25, 42
Reiter S. 61
Rennert C. 45
Reuken P. A. 33
Reul W. 10, 13
Reutzel-Selke A. 51
Rey J. 27, 48
Ribback S. 50, 52
Riedel A. 41
Rincón D. 33
Ring S. 42
Rinker F. 57
Ripoll C. 16, 33
Rizzo L. Y. 53
Rochlitz K. 15, 18, 21
Rockstroh J. K. 57, 60
Roderburg C. 16, 17, 47, 53
Roderfeld M. 15, 22, 34
Rodriguez L. Z. 53
Roeb E. 15, 22, 34
Roessler S. 49, 50
Rolf G. 43
RoseJohn S. 14
Roy S. 16, 17, 53
Roy-Chowdhury J. 24
Roy-Chowdhury N. 24
Rubner C. 47
Rufat P. 30
Ruiz-Margain A. 42
Rümmele P. 47
Rupp C. 30, 48
Rupp M. 61
Russo C. 59
Q
Quagliata L. 55
R
S
Ramadori P. 50
Raschzok N. 51
Rashidi-Alavijeh J. 27
Raszeja-Wyszomirska J. 40
Rattay S. 59
Rau M. 26
Rauber C. 30
Rausch M. 35
Real C. I. 58
Rebholz C. 38
Rehders A. 54
Reich M. 43, 54
Reichert M. 26, 32
Reif R. 13, 21
Reisinger F. 47
Saftig P. 14
Sahin H. 44
Sahle S. 13
Salcedo M. 33
Sallmon H. 51
Santosa D. 32
Sanwald J. 15
Sarrazin C. 35
Sastre Turrión B. 61
Sauer I. M. 51
Sauer P. 30
Sauer V. 24, 30
Saugspier M. 49
Sawitza I. 15, 33, 40
nd
Sawodny O. 15
Schäfer C. 38
Scharbatke E. C. 30
Scharf R. E. 20, 21
Schattenberg J. 26, 27, 51,
59
Scherbaum N. 58
Schierwagen R. 13, 16, 43
Schildberg F. 13
Schiller B. 19
Schindler K. 22
Schirdewahn T. 60
Schirmacher P. 13, 48, 49,
50
Schlaak J. F. 58
Schlaphoff V. 60
Schlitt H. J. 41, 47, 64
Schlune A. 39
Schmidt H. H.J. 24, 30
Schmidt L. 52
Schmidt M. 51
Schmidt-Arras D. 14
Schmidt-Heck W. 18, 44
Schmithals C. 54
Schmitt J. 25, 45
Schneider F. 15, 34
Schnitzbauer A. A. 55
Schott T. 34
Schramm C. 14, 24, 61
Schreier B. 18
Schubert S. 38
Schulte am Esch J. 54
Schulze zur Wiesch J. 58
Schulze-Osthoff K. 60
Schumacher E. C. 17
Schupp A.-K. 25, 59
Schwarze-Zander C. 57, 60
Schwinge D. 14
Sebode M. 24
Seddek A. 13
Sedlacek R. 14
Seehofer D. 51
Seitz H. K. 41
Seiz P. L. 60
Sekyere S. O. 60
Senff T. 58
Shafigullina A. 38
Sheikh N. 40
Shen Z. 16
- 74 -
Siefert J. 51
Singer S. 50
Sini M. 50
Sivanathan V. 27
Solanki M. 53
Sollinger D. 27
Sommer L. 35
Sommerfeld A. 22, 43, 45
Sonntag R. 53
Sotlar K. 48
Spengler U. 25, 57, 60, 61
Spitzhorn L.-S. 33
Spitzley S. 59
Spomer L. 21, 25
Sprinzl M. 35, 52, 59
Staffer S. 42
Stallmach A. 33
Steffen B. T. 20
Steffens H. 28, 29
Stella J. 30
Stengel S. H. 33
Stickel F. 41
Stindt J. 39
Stindt S. 59
Stoeber R. 44
Stokes C. S. 31, 35
Stoldt V. 20, 21
Strand S. 53
Strassburg C. 13, 16, 25, 29,
36, 43, 57, 60, 61
Straub B. K. 48
Streetz K. L. 44
Stremmel W. 21, 30, 39, 42,
59
Strnad P. 30, 31, 41, 48, 50
Strücker B. 51
Su J. 21
Suneetha P. V. 60
Susser S. 35
Sutton A. 30
T
Tacke F. 13, 16, 17, 20, 27,
31, 47, 50, 53
Tal A. 51
Talab A. 54
Tang P. 51
Tar K. 24
Targett-Adams P. 61
Tautenhahn H. M. 47
Tchaikovskaya T. 24
Teuber G. 28, 29
Teufel A. 17, 47, 48
Teutsch M. 35
Thasler W. E. 19, 41, 48, 49
Thimme R. 32, 58, 61
Thomas B. 34
Thomas M. 43, 52
Thonig A. 16
Thöns C. 58
Thorgeirsson S. S. 48, 52
Tiegs G. 14, 18, 19, 24
Tihaa L. 20
Tiller T. 39
Timm J. 58
TirnitzParker J. E. 14
Tony H.P. 30
Topp S. A. 54
Trautwein C. 13, 16, 17, 20,
25, 27, 30, 31, 41, 42, 44,
47, 48, 50, 53
Trebicka J. 13, 16, 29, 36,
43
Trojan J. 51
Trottier J. 40
Tsay H. C. 22
Tschuschner A. 15, 22, 34
TumaKellner S. 39, 59
U
Uder C. 47
Ulrich F. 55
Uschner F. 13, 43
Utpatel K. 50
V
Vaillant A. 58
van Bömmel F. 34, 35, 61,
62
Van de Leur E. 20
Vella G. 41
Venna V. 24
Verheugd P. 47
Vermehren A. 35
Vermehren J. 35
Vlaic S. 40
Voetlause R. 24
Vogel A. 61
nd
Volz T. 57, 60
vom Dahl S. 32, 39
von Bergen M. 14
Vonnahme M. 36
Vossbeck J. 32
Vucur M. 47
W
Waidmann O. 51, 54, 55
Waisman A. 51
Waldburger N. 48, 49
Walle H. 35
Walter S. 38
Walther T. 13
Wammers M. 25
Wan F. 19
Wan S. 50
Wandrer F. 60
Wang J. M. 17
Wang X. 24
Wannhoff A. 30, 42
Warzecha K. T. 31
Weber B. 28, 29
Weber M. M. 26
Weber S. N. 38
Wedemeyer H. 35, 57, 60
Wege H. 34
Wegscheid C. 19, 24
Wehmeyer M. 34
Wei W. 39
Weigert A. 54
Weiler S. 50
Weiler-Normann C. 24
Weinmann A. 59
Weiskirchen R. 18, 19, 20,
53
Weiss J. 30
Weiss K.H. 30
Weiss T. 39, 40, 44
Weißbrich B. 30
Wells R. G. 16
Welzel T. 35
Weng H. 55
Weng H.L. 16
Werner J. M. 41
Werner M. 58
Werner T. 34
Wetzel S. 14
Wewering F. 14
- 75 -
Widera A. 18, 21, 44
Wieczorek K. 48
Willuweit K. 27
Winkler S. 52
Wirth T. 51
Wissenbach D. K. 14
Wissniowski T. 49
Witthöft T. 28, 29
Wittum G. 61
Wöhler C. 28
Wohlfahrt J. 25
Wöhner B. 14
Wolf A. 18
Wolf D. 36
Wolf S. 52
Wolf T. 50
Wolff A. 49
Wolter F. 57, 60, 61
Wörns M. 27, 51, 52, 53
Wranke A. 60
Wruck W. 27, 33, 42
X
Xu H. C. 57
Y
Yotti R. 33
Youssef S. A. 25
Yuan Q. 22
Z
Zacarias-Föhrding L. 54
Zanger U. M. 52
Zehnter E. 28, 29
Zellmer S. 14
Zenouzi R. 24
Zeuzem S. 35, 51, 54
Zhang W. 24
Zhao G. 42
Zibert A. 30
Zimmer S. 43
Zimmer V. 26, 32, 40
Zimmermann A. 26, 59
Zimmermann H. W. 25, 31,
42, 50
Zimmermann T. 26, 59
Ziol M. 31
Zipprich A. 16, 18
Zobeley C. 26
Zoubek M. E. 42
EIN NEUES UNTERNEHMEN.
EINE LANGE TRADITION.
AbbVie vereint die Dynamik und Fokussierung
eines Biotech-Unternehmens mit mehr als
125 Jahren Erfahrung eines forschenden Arzneimittelherstellers.
Unser Ziel ist es, die Gesundheit und Lebensqualität von Patienten zu verbessern. Dies
erreichen wir durch innovative Spezialmedikamente und zielgerichtete Forschung.
2.400 AbbVie Mitarbeiter arbeiten an
unserem Hauptsitz in Wiesbaden und an
unserem Forschungs- und Produktionsstandort in Ludwigshafen für dieses Ziel.
abbvie.de
nd
MENSCHEN. MÖGLICHKEITEN.
LEIDENSCHAFT.
- 76 -
0$+7B$LQGG

Programm zur GASL 2016

Transcription

Similar documents

Impfschutz für alle

PDF zum

Aaseth-Bylow - Neenah Public Library

gemeinde kronshagen

Prof. Dr. med. Michael Nauck - Deutsche Diabetes Gesellschaft

Programm - Deutsche Gesellschaft für Urologie

Beipackzettel Opipramol-neuraxpharm® 50 mg, Filmtbl.